{"gene":"ATP2A2","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":1999,"finding":"Mutations in ATP2A2 (encoding SERCA2, a sarco/endoplasmic reticulum Ca2+-ATPase) cause Darier disease; frameshift, in-frame, splice-site, and missense mutations in functional domains were identified, establishing that SERCA2 loss-of-function disrupts a Ca2+-signalling pathway regulating keratinocyte cell-to-cell adhesion and differentiation.","method":"Mutation screening of ATP2A2 gene in DD families; identification of 13 mutations in functional domains","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 / Strong — direct mutation identification in functional domains replicated across multiple families, foundational mechanistic link between SERCA2 and keratinocyte adhesion/differentiation","pmids":["10080178"],"is_preprint":false},{"year":2003,"finding":"Steady-state and rapid kinetic analyses of SERCA2a and SERCA2b isoforms revealed: SERCA2b has 10-fold lower Ca2+ dissociation rate from E1Ca2 (true high Ca2+ affinity) and slower dephosphorylation than SERCA2a; both SERCA2 isoforms show 2-fold slower E2→E1Ca2 transition than SERCA1a. Ten Darier disease mutants were functionally characterized: uncoupling of Ca2+ translocation from ATP hydrolysis and/or altered partial reaction rates (E1~P→E2-P block, E2-P→E2 rate reduction, or loss of phosphorylation) account for loss of function in 7/10 mutants.","method":"Heterologous expression in HEK-293 cells; steady-state and transient kinetic analyses; radioactive Ca2+ transport and phosphorylation assays","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 / Strong — rigorous in vitro kinetic characterization with multiple mutants and isoforms, multiple orthogonal biochemical methods","pmids":["12975374"],"is_preprint":false},{"year":2001,"finding":"Mice heterozygous for a null Atp2a2 allele (SERCA2 haploinsufficiency) develop squamous cell tumors of forestomach, esophagus, oral mucosa, tongue, and skin, without loss of heterozygosity, establishing that reduced SERCA2 Ca2+ pump levels predispose keratinocytes to neoplasia as a primary initiating event.","method":"Atp2a2+/- mouse model; Western blot; histopathology; comparison with age/sex-matched wild-type controls","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — defined loss-of-function mouse model with clear phenotypic readout, confirmed by Western blot and histology","pmids":["11389134"],"is_preprint":false},{"year":2001,"finding":"In SERCA2+/- mice, reduced SERCA2 causes shorter cytosolic Ca2+ transients (due to compensatory upregulation of specific plasma membrane Ca2+ pump isoforms) and ~50% reduction in Ca2+ oscillation frequency, yet agonist-stimulated exocytosis is preserved through adaptive upregulation of Ca2+ sensors synaptotagmins I and III, making exocytosis ~10-fold more sensitive to Ca2+.","method":"SERCA2+/- mouse model; Ca2+ imaging; exocytosis assays; Western blot for synaptotagmins and plasma membrane Ca2+ pumps","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods in a clean genetic model with defined molecular readouts","pmids":["11387203"],"is_preprint":false},{"year":2008,"finding":"HAX-1 (anti-apoptotic protein) binds directly to SERCA2 via residues 575–594 of SERCA2's nucleotide-binding domain interacting with HAX-1 C-terminal domain (aa 203–245). Overexpression of HAX-1 downregulates SERCA2 protein levels, reduces ER Ca2+ stores, and promotes cell survival after hypoxia/reoxygenation or thapsigargin treatment; conversely, SERCA2 overexpression abrogates HAX-1's pro-survival effect.","method":"Co-immunoprecipitation; deletion mapping; transfection in HEK-293 cells; immunofluorescence; cell viability assays","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal binding domain mapping, functional rescue/overexpression experiments with multiple readouts in single lab","pmids":["18971376"],"is_preprint":false},{"year":2009,"finding":"Calumenin (a luminal EF-hand Ca2+-binding protein) interacts with SERCA2 via its residues 132–222 binding to SERCA2 luminal domain L4 (aa 853–892). The interaction is favored in the E1 conformation of SERCA2 (reduced by thapsigargin, vanadate, or ATP). Calumenin knockdown increases SERCA2 Ca2+ sensitivity and enhances Ca2+ transient amplitude in cardiomyocytes.","method":"GST pulldown; co-immunoprecipitation; calumenin knockdown in HL-1 cells; oxalate-supported Ca2+ uptake assay; immunocytochemistry","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — in vitro binding domain mapping, functional Ca2+ measurements with KD, multiple orthogonal methods in single lab","pmids":["19740751"],"is_preprint":false},{"year":2012,"finding":"VEGF activates SERCA2b via •NO-mediated S-glutathiolation of cysteine-674, which stimulates ER Ca2+ uptake and is required for VEGF-induced endothelial cell Ca2+ influx and migration. A C674S SERCA2b mutant is unresponsive to VEGF/•NO-stimulated migration and Ca2+ uptake, and overexpression of glutaredoxin-1 (which reverses S-glutathiolation) blocks these effects.","method":"45Ca2+ uptake assay; SERCA2b C674S mutagenesis; adenoviral overexpression; immunochemical detection of S-glutathione adducts; SERCA2 knockdown; Ca2+ imaging","journal":"Antioxidants & redox signaling","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstitution via mutagenesis, multiple orthogonal methods (transport assay, migration assay, S-glutathiolation detection, KD), single lab","pmids":["22472004"],"is_preprint":false},{"year":2015,"finding":"Phosphodiesterase 3A1 (PDE3A1) interacts with SERCA2 in a phosphorylation-dependent manner: PKA phosphorylation of PDE3A1 at Ser-292/Ser-293 (unique N-terminal site) promotes its incorporation into a SERCA2/AKAP18 signalosome in human sarcoplasmic reticulum, where it controls a local cAMP pool regulating phospholamban phosphorylation and SERCA2 activity. Deletion of the PDE3A1/2 N-terminus blocks SERCA2 interaction.","method":"Co-immunoprecipitation; gel filtration chromatography; immunohistochemistry; recombinant protein interaction assays; serine-to-alanine mutagenesis; SR Ca2+ uptake assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP with recombinant proteins, mutagenesis mapping, functional cAMP/Ca2+ assays, single lab with multiple orthogonal methods","pmids":["25593322"],"is_preprint":false},{"year":2023,"finding":"SERCA2 phosphorylation at serine 663 is increased in ischemic human and mouse hearts. Preventing S663 phosphorylation significantly increases SERCA2 activity and protects against cytosolic and mitochondrial Ca2+ overload and cell death, establishing S663 phosphorylation as a negative regulator of SERCA2 activity and a pathophysiological event in cardiac ischemia-reperfusion.","method":"Phosphorylation analysis in human ischemic hearts; mutagenesis; SERCA2 activity assays; cytosolic/mitochondrial Ca2+ measurements; cell death assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Moderate — human tissue validation combined with mechanistic mutagenesis and functional Ca2+ measurements in multiple cell lines","pmids":["37291092"],"is_preprint":false},{"year":2023,"finding":"PDE3A binds directly to SERCA2 via PDE3A amino acids 277–402 interacting with SERCA2 actuator domain (aa 169–216). Disruption of this interaction with a peptide disruptor (OptF) increases SERCA2 activity independently of PLB and PKA, reduces cardiac mortality after aortic banding in mice, and has no effect in cardiomyocyte-specific SERCA2-inactivated mice, confirming the mechanism is SERCA2-dependent.","method":"Surface plasmon resonance; proximity ligation assay; peptide arrays; immunoprecipitation; SR Ca2+ uptake in cardiomyocytes and HEK293 vesicles; rAAV9 in vivo gene delivery; echocardiography; cardiac MRI","journal":"Circulation","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — direct binding characterization, mutagenesis/deletion mapping, functional assays in multiple systems including in vivo rescue, confirmed in SERCA2-KO control","pmids":["36876489"],"is_preprint":false},{"year":2021,"finding":"AKAP18δ anchors CaMKIIδ to SERCA2-PLN and RYR complexes via two distinct regions: AKAP18δ-N inhibits CaMKIIδ (and binds CaM), while AKAP18δ-C activates CaMKIIδ by lowering the Ca2+ threshold and inducing CaM trapping. AKAP18δ-C facilitates faster Ca2+ reuptake via SERCA2, while AKAP18δ-N has opposite effects, defining AKAP18δ as both a CaM-KAP and a CaMKII regulator at SERCA2-PLN.","method":"Peptide arrays; co-immunoprecipitation; pulldown; proximity ligation; FRET-based CaMKII activity assay; SR vesicle Ca2+ imaging; surface plasmon resonance; AlphaScreen; adenovirus/AAV transduction","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods including direct binding, functional kinase and Ca2+ assays, in vivo confirmation","pmids":["34814703"],"is_preprint":false},{"year":2020,"finding":"JNK2 (but not JNK1) associates with and phosphorylates SERCA2, increasing SERCA2 ATPase maximal rate (without altering Ca2+ affinity) and SR Ca2+ content load. This JNK2-driven SERCA2 activation is CaMKII-independent and, combined with JNK2-CaMKII-driven SR Ca2+ leak, exacerbates atrial arrhythmogenicity.","method":"Co-immunoprecipitation; biochemical phosphorylation assay; confocal Ca2+ imaging; SERCA2 ATPase activity assay; optical mapping in intact hearts; JNK-specific inhibition","journal":"Circulation research","confidence":"High","confidence_rationale":"Tier 2 / Moderate — direct binding shown by Co-IP, enzymatic activity directly measured, functional Ca2+ and arrhythmia readouts, multiple orthogonal methods","pmids":["33334123"],"is_preprint":false},{"year":2023,"finding":"MFN2 (mitofusin-2) interacts with ER-embedded SERCA2, enhancing mitochondria-ER contact and facilitating mitochondrial Ca2+ influx required for mitochondrial metabolism. MFN2 also stimulates SERCA2 ER Ca2+ retrieval activity, preventing excessive mitochondrial Ca2+ accumulation and apoptosis in CD8+ T cells. The beneficial effects were largely prevented in SERCA2-knockout mice.","method":"Co-immunoprecipitation; proximity ligation assay; genetic ablation of Mfn2 in CD8+ T cells; SERCA2-knockout mice; mitochondrial Ca2+ and metabolism measurements","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — reciprocal Co-IP, genetic KO validation in two orthologous models, multiple functional readouts","pmids":["37738362"],"is_preprint":false},{"year":2014,"finding":"Darier disease keratinocytes display constitutive ER stress with impaired membrane localization of desmosomal cadherins (Dsg3, Dsc3), desmoplakin, E-cadherin, and catenins (retained in ER), and reduced intercellular adhesion strength. SERCA2 inhibition by thapsigargin in normal keratinocytes recapitulates these abnormalities, establishing SERCA2 loss-of-function as the cause of ER stress and defective desmosome/adherens junction formation in DD.","method":"Immunostaining; co-immunostaining with ER markers; dispase mechanical dissociation assay; thapsigargin treatment of normal keratinocytes; Miglustat pharmacological rescue","journal":"The Journal of investigative dermatology","confidence":"High","confidence_rationale":"Tier 2 / Moderate — loss-of-function (DD keratinocytes + chemical inhibitor) with multiple molecular and functional readouts, pharmacological rescue","pmids":["24390139"],"is_preprint":false},{"year":2012,"finding":"SERCA2b loss-of-function (via thapsigargin inhibition or siRNA) in keratinocytes increases sphingosine levels and decreases sphingosine kinase (SPHK1) expression. Inhibiting sphingosine lyase rescues defects in keratinocyte differentiation, E-cadherin localization, desmoplakin translocation, and ER Ca2+ sequestration caused by SERCA2 inhibition, linking SERCA2-controlled ER Ca2+ to sphingolipid signaling in keratinocyte adhesion.","method":"SERCA2b siRNA knockdown; thapsigargin inhibition; sphingolipid pathway inhibitors; immunofluorescence; Ca2+ sequestration assay","journal":"The Journal of investigative dermatology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined molecular pathway readouts, pharmacological pathway rescue, single lab","pmids":["22277942"],"is_preprint":false},{"year":2011,"finding":"SERCA2 mutant proteins associated with Darier disease are less soluble, aggregate, and are more polyubiquitinated in keratinocytes. Aggregated SERCA2 mutants (not ER Ca2+ depletion per se) initiate ER stress. Mutant SERCA2 aggregates in primary human keratinocytes cause cell rounding, detachment, and apoptosis; conversely, SERCA2 knockdown renders cells resistant to apoptosis.","method":"Expression of DD mutants in primary human keratinocytes; solubility/aggregation assays; ubiquitination assay; ER stress markers; cell death/apoptosis assays; SERCA2 knockdown","journal":"Journal of cell science","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — systematic analysis of multiple mutants with orthogonal assays in primary cells, single lab","pmids":["22045735"],"is_preprint":false},{"year":2005,"finding":"Haploinsufficiency of Atp2a2 predisposes mice to squamous cell tumors via a novel mechanism not involving loss of heterozygosity (tumor cells retain the wild-type allele and express SERCA2 protein), absence of ras mutations, and upregulation of wild-type K-ras. Affected epithelium shows overexpression of hyperactivation-associated keratins as early as 2 months of age.","method":"Laser capture microdissection; immunoblot; immunohistochemistry; ras mutation analysis; Atp2a2+/- mouse model","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic mouse model with molecular characterization of tumor mechanism, multiple analytical methods, single lab","pmids":["16204033"],"is_preprint":false},{"year":2009,"finding":"Reduced SERCA2 abundance (53% reduction) in inducible cardiomyocyte-specific knockout mice decreases SR Ca2+ content, Ca2+ transient amplitude and decay, and reduces the propensity for arrhythmogenic Ca2+ wave development (waves in 31% KO vs 57% WT cardiomyocytes) and ventricular extrasystoles.","method":"Inducible cardiomyocyte-specific Serca2 gene disruption; Fluo-5F Ca2+ imaging; whole-cell voltage clamp; in vivo ECG","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean inducible KO model with multiple Ca2+ imaging and electrophysiology readouts, single lab","pmids":["20019150"],"is_preprint":false},{"year":2012,"finding":"PPAR-γ directly binds a PPAR response element in the proximal SERCA2 gene promoter (−259 bp region) and transactivates SERCA2b expression in pancreatic β-cells. CDK5-induced phosphorylation of PPAR-γ at Ser-273 reduces SERCA2 expression; pioglitazone (PPAR-γ agonist) prevents this by blocking CDK5-mediated PPAR-γ phosphorylation, restoring SERCA2b levels and protecting against ER stress-induced β-cell death.","method":"Luciferase reporter assay; EMSA; chromatin immunoprecipitation; CDK5 inhibitor (roscovitine); Ca2+ imaging; insulin secretion assay","journal":"Molecular endocrinology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and EMSA, functional rescue with pharmacological tools, single lab","pmids":["22240811"],"is_preprint":false},{"year":2010,"finding":"Mitochondrial transcription factors TFAM and TFB2M bind to the −122 to −114 nt (TFAM) and −122 to −117 nt (TFB2M) regions of the Serca2 gene promoter in the nucleus of cardiac myocytes, directly regulating SERCA2 gene transcription. Mutation of these binding sites reduces Serca2 transcription.","method":"Chromatin immunoprecipitation; fluorescence correlation spectroscopy; luciferase reporter with promoter mutations; immunostaining (nuclear localization); overexpression in cardiac myocytes","journal":"Cardiovascular research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct ChIP-confirmed binding with functional mutagenesis validation, single lab","pmids":["21113058"],"is_preprint":false},{"year":2020,"finding":"SERCA2 is O-GlcNAcylated in mouse and human β-cells (identified via OGT-dependent modification), and pharmacological SERCA2 activation rescues palmitate-stimulated insulin secretion in OGT-deficient islets, establishing O-GlcNAcylation of SERCA2 as a mechanism coupling nutrient sensing to β-cell ER Ca2+ function and lipid-potentiated insulin secretion.","method":"β-cell-specific OGT knockout mice; O-GlcNAc proteomics; pharmacological SERCA2 activation (CDN1163); insulin secretion assay; in vivo hyperinsulinemic clamp","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model combined with pharmacological rescue and identification of PTM on SERCA2, single lab","pmids":["32375037"],"is_preprint":false},{"year":2020,"finding":"TG2 (transglutaminase 2) mediates serotonylation of SERCA2 (covalent modification by serotonin) under hypoxia, inhibiting SERCA2 activity and increasing intracellular Ca2+ via TRPC6. TG2 gene silencing or knockout prevents hypoxia-induced SERCA2 serotonylation and attenuates pulmonary vascular remodeling and hypertension in vivo.","method":"Co-immunoprecipitation; SERCA2 activity assay; TG2 gene silencing/overexpression; TG2 vascular smooth muscle-specific knockout mice; Fluo-4AM Ca2+ measurement","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP identification of modification, functional activity assay, conditional KO in vivo, single lab","pmids":["32116663"],"is_preprint":false},{"year":2020,"finding":"Inactivation of SERCA2 cysteine 674 (C674S knock-in mice) causes intracellular Ca2+ accumulation that activates calcineurin, promoting nuclear translocation of NFAT and NFκB, resulting in smooth muscle cell phenotypic modulation and accelerating angiotensin II-induced aortic aneurysm development. Calcineurin inhibition reverses SMC modulation.","method":"SERCA2 C674S knock-in mouse model; calcineurin inhibitors; NFAT/NFκB nuclear translocation assay; angiotensin II aneurysm model; intracellular Ca2+ measurement","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knock-in model with defined molecular pathway, pharmacological pathway inhibition, single lab","pmids":["32035136"],"is_preprint":false},{"year":2022,"finding":"Sigma-1 receptor (Sigmar1) interacts with SERCA2 at residue Q615, and promotes SERCA2 proteasomal degradation through Hrd1/Sel1L-dependent ER-associated degradation (ERAD), with ubiquitination of SERCA2 at K460 and K541 mediating degradation. This Sigmar1-SERCA2 axis attenuates osteoclastogenesis.","method":"IP-mass spectrometry; co-immunoprecipitation; site-directed mutagenesis; ubiquitination assay; Sigmar1 agonist/antagonist treatment; Sigmar1 KO mice; osteoclast differentiation assay","journal":"EMBO molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — IP-MS followed by co-IP validation, residue-level mutagenesis, and in vivo KO model, single lab","pmids":["35611810"],"is_preprint":false},{"year":2021,"finding":"Brain-specific heterozygous loss of Atp2a2 in mice results in decreased ER Ca2+ uptake activity, slower cytosolic Ca2+ decay after neuronal depolarization, and elevated extracellular dopamine levels in the nucleus accumbens (measured by in vivo dialysis), linking SERCA2 haploinsufficiency in neurons to enhanced dopamine signaling and behavioral abnormalities.","method":"Brain-specific conditional Atp2a2 heterozygous KO mice; ER Ca2+ uptake assay in brain membranes; neuronal Ca2+ imaging; in vivo microdialysis; behavioral testing","journal":"Human molecular genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean conditional KO with direct Ca2+ measurements and in vivo neurochemistry, single lab","pmids":["34104969"],"is_preprint":false},{"year":1997,"finding":"The relative ratio of phospholamban to SERCA2 is a critical determinant of myocardial contractility: cardiac muscles with lower PLB:SERCA2 ratios (atria vs. ventricle, 4.2-fold lower) show 3-fold faster rates of force development and relaxation; phospholamban knockout hearts (no PLB) show enhanced contractility parameters, establishing PLB as a reversible inhibitor of SERCA2 whose relief by phosphorylation regulates diastolic relaxation.","method":"Comparison of atrial vs. ventricular contractility; phospholamban knockout mouse hearts; isolated work-performing heart left-ventricular pressure measurements; Western blot for PLB and SERCA2","journal":"Basic research in cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic KO model plus quantitative protein ratio analysis with functional cardiac readouts, single lab","pmids":["9202840"],"is_preprint":false},{"year":2014,"finding":"ERK1/2 activation during cardiac hypertrophy represses SERCA2 transcription via nuclear factor-κB (NFκB); pharmacological ERK inhibitors preserve SERCA2 mRNA during hypertrophy, and ERK activation alone is sufficient to reduce SERCA2 mRNA, establishing an ERK→NFκB→SERCA2 repression pathway.","method":"Neonatal rat ventricular myocyte hypertrophy model; pharmacological ERK inhibitors; NFκB inhibitors; RT-PCR; SERCA2 promoter reporter assay","journal":"Journal of molecular and cellular cardiology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological pathway dissection with reporter assay and mRNA measurement, multiple inhibitors, single lab","pmids":["25008120"],"is_preprint":false},{"year":2023,"finding":"SERCA2-deficient β-cells (βS2KO mice) have reduced ER Ca2+ levels and show decreased expression of active proinsulin processing enzymes PC1/3 and PC2, mis-localization of proinsulin and proPC2 to the ERGIC/cis-Golgi, and increased circulating proinsulin, establishing that SERCA2 regulates prohormone trafficking and processing enzyme maturation through ER Ca2+ homeostasis.","method":"β-cell-specific SERCA2 KO mice; Ca2+ imaging; RNA-seq; immunofluorescence; proinsulin processing assays; SERCA2-deficient INS-1 cells","journal":"Diabetologia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean cell-type-specific KO model with mechanistic trafficking and processing readouts, confirmed in INS-1 cell model","pmids":["37537395"],"is_preprint":false},{"year":2023,"finding":"SERCA2 interacts with LC3B via an LIR motif, facilitating WIPI2-independent autophagosome formation in triple-negative breast cancer cells. Autophagy-mediated SERCA2 degradation triggers transcriptional upregulation of SERCA2 through a Ca2+/CaMKK/CREB-1 feedback loop.","method":"Co-immunoprecipitation; LIR motif analysis; autophagy flux assays; SERCA2 knockdown/overexpression; Ca2+/CaMKK pathway inhibition; CREB reporter assay","journal":"Acta pharmaceutica Sinica. B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP binding, pathway pharmacological dissection with functional readouts, single lab","pmids":["36561988"],"is_preprint":false},{"year":2013,"finding":"FE65 interacts with SERCA2 in human brain tissue, validated by pulldown/mass spectrometry and co-immunoprecipitation. FE65 knockout neurons show upregulation of SERCA2, and FE65 knockdown in HEK293T cells increases sensitivity to thapsigargin, suggesting FE65 modulates intracellular Ca2+ homeostasis via SERCA2.","method":"Pulldown/mass spectrometry from human brain tissue; co-immunoprecipitation; FE65/FE65L1 double KO mouse proteomics; FE65 siRNA knockdown; thapsigargin sensitivity assay","journal":"Molecular & cellular proteomics","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — Co-IP validated in human brain, functional link to SERCA2 only via sensitivity assay, limited mechanistic follow-up","pmids":["24284412"],"is_preprint":false},{"year":2008,"finding":"FOG-2 (friend of GATA-2) physically interacts with thyroid hormone receptor-α1 and abrogates T3-mediated SERCA2 promoter activity and expression; cardiac-specific FOG-2 overexpression in mice reduces SERCA2 transcript and protein levels, depresses cardiac function, and activates fetal gene program.","method":"Co-immunoprecipitation of FOG-2 with TR-α1; luciferase reporter assay of SERCA2 promoter; FOG-2 transgenic mice; Western blot; RT-PCR","journal":"Circulation research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct protein interaction plus in vivo transgenic model with SERCA2 functional readout, single lab","pmids":["18658259"],"is_preprint":false},{"year":2023,"finding":"SERCA2 loss in retinal neurons occurs in ocular hypertension and optic nerve crush injury in mice and patients with primary open-angle glaucoma. Pharmacological SERCA2 activation or neuron-specific SERCA2 gene delivery rescues single-cell cytosolic Ca2+ clearance dynamics, reduces ER stress, promotes neuronal survival, and restores visual function in injured mice.","method":"Two-photon microscopy Ca2+ imaging; rAAV-mediated SERCA2 neuron-specific gene delivery; pharmacological SERCA2 activation; ER stress markers; retinal ganglion cell survival assay; visual behavior testing","journal":"Cell reports. Medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct Ca2+ dynamics measurement with gene-delivery rescue plus pharmacological activation, multiple orthogonal functional readouts","pmids":["39615485"],"is_preprint":false},{"year":2022,"finding":"SERCA2 oxidation (via xanthine oxidase activation) and inactivation is a key intermediary in ischemia/reperfusion-induced endothelial dysfunction: DAPA inhibits XO-mediated SERCA2 oxidation, preventing cytoplasmic Ca2+ overload and CaMKII activation, and the protective effects of DAPA on microvascular integrity are largely abrogated in SERCA2-knockout mice.","method":"SERCA2 knockout mice; human coronary artery endothelial cells; hypoxia/reoxygenation model; Western blot for SERCA2 oxidation; CaMKII activity assay; Ca2+ imaging","journal":"Theranostics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — SERCA2-KO used as mechanistic control, Ca2+ and kinase activity measurements, single lab","pmids":["35836807"],"is_preprint":false},{"year":1998,"finding":"The SERCA2 gene contains a muscle-specific enhancer in its distal promoter (−1467 to −1105 bp). An E box/AT-rich element at −1115 bp is critical for maximal enhancer activity and binds a muscle-induced nuclear protein complex; CArG and MCAT elements within this region also bind specific nuclear factors and contribute to overall SERCA2 promoter activation in muscle cells.","method":"Deletion analysis; heterologous TK promoter assay in Sol8 muscle cells; gel mobility shift assay; mutagenesis of cis-elements","journal":"Nucleic acids research","confidence":"Medium","confidence_rationale":"Tier 1–2 / Moderate — functional enhancer mapping with mutagenesis and gel shift, single lab","pmids":["9461473"],"is_preprint":false},{"year":2021,"finding":"Cardiac troponin I (cTnI, encoded by TNNI3) translocates to the nucleus in cardiomyocytes and directly binds to the Atp2a2 promoter region (−239 to −889 bp) at a CCAT motif. TNNI3 gain-of-function increases and loss-of-function decreases SERCA2 mRNA and protein levels, and increases Atp2a2 promoter activity in a luciferase reporter assay.","method":"ChIP-seq; luciferase reporter assay; TNNI3 siRNA knockdown and overexpression; Western blot; Ca2+ transient measurement","journal":"Genes & diseases","confidence":"Low","confidence_rationale":"Tier 3 / Moderate — ChIP-seq binding and reporter assay validated, but single lab with limited mechanistic follow-up on the SERCA2 regulation mechanism","pmids":["36157491"],"is_preprint":false},{"year":2023,"finding":"SERCA2 depletion in CRISPR/Cas9-generated human keratinocytes lacking SERCA2 causes excess MAPK/ERK signaling and deficiency of desmosomal and cytoskeletal proteins, weakening intercellular adhesion. MEK inhibition rescues adhesive protein expression and keratinocyte sheet integrity even in SERCA2-depleted or SERCA2-inhibited cells, positioning ERK signaling downstream of SERCA2 loss in Darier disease pathogenesis.","method":"CRISPR/Cas9 SERCA2 knockout in human keratinocytes; organotypic epidermis; RNA-seq; proteomics; immunostaining; MEK inhibitor treatment; dispase sheet integrity assay","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — human genetic KO model with omics and functional rescue, patient biopsy validation, multiple orthogonal methods","pmids":["37561594"],"is_preprint":false}],"current_model":"ATP2A2/SERCA2 is a P-type Ca2+-ATPase of the sarco/endoplasmic reticulum that pumps cytosolic Ca2+ into the ER lumen via an E1/E2 transport cycle; its activity is regulated by direct protein interactions (phospholamban inhibition relieved by PKA/CaMKII phosphorylation, PDE3A1 inhibition via actuator-domain binding, AKAP18δ-anchored CaMKIIδ regulation, calumenin inhibition from the ER lumen, HAX-1-mediated protein level control, and MFN2-mediated ER-mitochondria tethering), by post-translational modifications (S-glutathiolation of C674 activating the pump, serotonylation and S663 phosphorylation inhibiting it, K460/K541 ubiquitination targeting it for ERAD), and by transcriptional regulation (PPAR-γ, TFAM/TFB2M, calcineurin/NFAT pathway, ERK/NFκB repression, thyroid hormone receptor/FOG-2 axis); loss-of-function mutations cause Darier disease through ER stress, impaired desmosome/adherens junction assembly downstream of SERCA2 via ERK hyperactivation, while haploinsufficiency predisposes to squamous cell tumors and neuropsychiatric phenotypes via prolonged cytosolic Ca2+ transients and enhanced dopamine signaling."},"narrative":{"mechanistic_narrative":"ATP2A2 encodes SERCA2, a sarco/endoplasmic reticulum P-type Ca2+-ATPase that pumps cytosolic Ca2+ into the ER/SR lumen through an E1/E2 transport cycle, thereby controlling intracellular Ca2+ homeostasis across keratinocytes, cardiomyocytes, neurons, β-cells, and endothelium [PMID:12975374, PMID:11387203]. The pump exists as kinetically distinct SERCA2a and SERCA2b isoforms; rapid-kinetic analysis defined the partial reactions of the catalytic cycle and showed that Darier disease mutations uncouple Ca2+ translocation from ATP hydrolysis or block specific phosphoenzyme transitions [PMID:12975374]. SERCA2 activity is tuned by a network of direct protein partners and post-translational modifications: phospholamban acts as a reversible inhibitor whose phosphorylation relieves suppression to accelerate cardiac relaxation [PMID:9202840], PDE3A binds the actuator domain to constrain a local cAMP pool [PMID:25593322, PMID:36876489], AKAP18δ anchors CaMKIIδ at the SERCA2-PLN complex to bidirectionally control Ca2+ reuptake [PMID:34814703], JNK2 phosphorylates and activates the pump [PMID:33334123], luminal calumenin inhibits it in the E1 state [PMID:19740751], HAX-1 controls its protein level [PMID:18971376], and MFN2 tethers it to mitochondria to govern mitochondrial Ca2+ supply [PMID:37738362]. The pump is further regulated by redox and covalent modifications—activating S-glutathiolation of Cys-674 [PMID:22472004] versus inhibitory serotonylation [PMID:32116663], Ser-663 phosphorylation [PMID:37291092], O-GlcNAcylation [PMID:32375037], and K460/K541 ubiquitination driving Sigmar1/Hrd1-Sel1L-dependent ERAD [PMID:35611810]—and at the transcriptional level by PPAR-γ, TFAM/TFB2M, ERK/NF-κB repression, and a thyroid hormone receptor/FOG-2 axis [PMID:22240811, PMID:21113058, PMID:25008120, PMID:18658259]. Loss-of-function mutations in ATP2A2 cause Darier disease, in which mutant SERCA2 aggregation and ER stress, ERK/MAPK hyperactivation, and disrupted sphingolipid signaling impair desmosome/adherens junction assembly and keratinocyte adhesion [PMID:10080178, PMID:24390139, PMID:37561594]. SERCA2 haploinsufficiency separately predisposes to squamous cell tumors without loss of heterozygosity and produces neuropsychiatric phenotypes through prolonged cytosolic Ca2+ transients and enhanced dopamine signaling [PMID:11389134, PMID:16204033, PMID:34104969].","teleology":[{"year":1999,"claim":"Established the genetic basis linking SERCA2 to an epidermal disease, defining the pump as essential for keratinocyte adhesion and differentiation rather than only muscle Ca2+ handling.","evidence":"Mutation screening of ATP2A2 across Darier disease families, identifying 13 mutations in functional domains","pmids":["10080178"],"confidence":"High","gaps":["Did not resolve how individual mutations alter pump catalysis","Did not establish the downstream signaling defect in keratinocytes"]},{"year":2003,"claim":"Resolved how disease mutations impair pump function at the level of the catalytic cycle, distinguishing SERCA2a/2b kinetics and assigning specific partial-reaction defects to mutants.","evidence":"Heterologous expression with steady-state and transient kinetic, Ca2+ transport, and phosphorylation assays in HEK-293 cells","pmids":["12975374"],"confidence":"High","gaps":["3/10 mutants not mechanistically explained","No high-resolution structural model of mutant transitions"]},{"year":2001,"claim":"Demonstrated in vivo consequences of reduced pump dosage—tumor predisposition and altered Ca2+ transient kinetics buffered by compensatory adaptations—showing haploinsufficiency is a primary initiating event.","evidence":"Atp2a2+/- mouse models with histopathology, Ca2+ imaging, exocytosis assays, and Western blot","pmids":["11389134","11387203"],"confidence":"High","gaps":["Mechanism connecting reduced pump to neoplasia not defined here","Compensatory pathways may differ across tissues"]},{"year":2008,"claim":"Identified HAX-1 as a direct partner controlling SERCA2 protein level and ER Ca2+ stores, linking pump abundance to apoptosis resistance.","evidence":"Reciprocal Co-IP with deletion mapping, transfection, and viability assays in HEK-293 cells","pmids":["18971376"],"confidence":"High","gaps":["Mechanism by which HAX-1 lowers SERCA2 levels unresolved","Physiological relevance in non-transfected tissue untested"]},{"year":2009,"claim":"Defined a luminal, conformation-selective inhibitory interaction (calumenin), broadening regulation of SERCA2 beyond the cytosolic face.","evidence":"GST pulldown, Co-IP, calumenin knockdown, and oxalate-supported Ca2+ uptake in HL-1 cells","pmids":["19740751"],"confidence":"High","gaps":["Structural basis of E1-state preference not determined","In vivo significance not tested"]},{"year":2012,"claim":"Showed redox modification activates the pump, establishing Cys-674 S-glutathiolation as a NO/VEGF-responsive activating switch governing endothelial Ca2+ and migration.","evidence":"C674S mutagenesis, 45Ca2+ uptake, S-glutathione adduct detection, glutaredoxin-1 overexpression, and migration assays","pmids":["22472004"],"confidence":"High","gaps":["Whether C674 modification operates similarly in other cell types not addressed","Crosstalk with other PTMs at the same residue unexplored"]},{"year":2012,"claim":"Connected SERCA2-controlled ER Ca2+ to sphingolipid signaling as a mediator of keratinocyte adhesion defects, providing a downstream pathway for Darier disease.","evidence":"SERCA2b siRNA and thapsigargin in keratinocytes with sphingolipid pathway inhibitors and adhesion/differentiation readouts","pmids":["22277942"],"confidence":"Medium","gaps":["Causal link between sphingosine and adhesion proteins correlative","Single lab without genetic SERCA2 model"]},{"year":2011,"claim":"Reframed Darier disease pathogenesis around mutant protein aggregation and ER stress rather than Ca2+ depletion per se.","evidence":"Expression of DD mutants in primary human keratinocytes with solubility, ubiquitination, ER stress, and apoptosis assays plus knockdown","pmids":["22045735"],"confidence":"Medium","gaps":["Aggregation vs depletion contributions not fully separated for all mutants","Single-lab primary cell system"]},{"year":2014,"claim":"Demonstrated SERCA2 loss recapitulates the DD adhesion phenotype via ER retention of junctional proteins and constitutive ER stress, with pharmacological rescue.","evidence":"DD keratinocytes and thapsigargin in normal keratinocytes with immunostaining, dispase dissociation, and Miglustat rescue","pmids":["24390139"],"confidence":"High","gaps":["Signaling intermediary between ER stress and junction assembly not yet identified","Chemical inhibition may not fully mimic genetic loss"]},{"year":2015,"claim":"Placed SERCA2 within a phosphorylation-dependent PDE3A1/AKAP18 signalosome that compartmentalizes cAMP to control phospholamban and pump activity.","evidence":"Co-IP, gel filtration, recombinant interaction assays, S-to-A mutagenesis, and SR Ca2+ uptake","pmids":["25593322"],"confidence":"High","gaps":["Stoichiometry and spatial organization of the signalosome not resolved","Functional consequences in vivo not tested here"]},{"year":2010,"claim":"Identified TFAM and TFB2M as direct nuclear transcriptional regulators of Serca2, expanding control beyond muscle-specific enhancers.","evidence":"ChIP, fluorescence correlation spectroscopy, and promoter-mutation luciferase reporters in cardiac myocytes","pmids":["21113058"],"confidence":"Medium","gaps":["Mechanism of nuclear localization of mitochondrial factors unclear","Physiological inducers of this regulation not defined"]},{"year":2012,"claim":"Defined a PPAR-γ/CDK5 transcriptional axis governing SERCA2b in β-cells, linking pump expression to metabolic ER-stress protection.","evidence":"Luciferase reporter, EMSA, ChIP, CDK5 inhibition, and insulin secretion/Ca2+ assays","pmids":["22240811"],"confidence":"Medium","gaps":["In vivo relevance of Ser-273 phosphorylation to SERCA2 not tested","Single lab"]},{"year":2014,"claim":"Established an ERK→NF-κB pathway that transcriptionally represses SERCA2 during cardiac hypertrophy, complementing the ERK-driven adhesion defects later seen in skin.","evidence":"Neonatal rat ventricular myocyte hypertrophy model with ERK/NF-κB inhibitors, RT-PCR, and promoter reporter","pmids":["25008120"],"confidence":"Medium","gaps":["Direct NF-κB binding site on SERCA2 promoter not mapped","Pharmacological dissection only"]},{"year":2020,"claim":"Expanded the PTM repertoire controlling SERCA2 across tissues—activating O-GlcNAcylation in β-cells, inhibitory TG2-mediated serotonylation in vascular smooth muscle, and calcineurin/NFAT-coupled C674 signaling in aneurysm—each tying pump regulation to a disease context.","evidence":"OGT-KO mice and O-GlcNAc proteomics; TG2 silencing/KO with activity and Ca2+ assays; C674S knock-in with calcineurin inhibitors and aneurysm model","pmids":["32375037","32116663","32035136"],"confidence":"Medium","gaps":["Modification site mapping incomplete for some PTMs","Crosstalk among coexisting modifications unresolved"]},{"year":2021,"claim":"Defined AKAP18δ as a dual CaM/CaMKIIδ regulator at the SERCA2-PLN complex and JNK2 as a CaMKII-independent activating kinase, refining kinase control of Ca2+ reuptake and arrhythmogenesis.","evidence":"Peptide arrays, Co-IP, PLA, SPR, FRET CaMKII assays, and SR Ca2+ imaging; Co-IP and ATPase assays with optical mapping for JNK2","pmids":["34814703","33334123"],"confidence":"High","gaps":["JNK2 phosphorylation site on SERCA2 not identified","Integration of opposing AKAP18δ-N/-C activities in vivo incompletely defined"]},{"year":2021,"claim":"Demonstrated neuronal SERCA2 haploinsufficiency slows Ca2+ decay and elevates accumbal dopamine, providing a mechanism for the neuropsychiatric phenotype associated with reduced pump dosage.","evidence":"Brain-specific conditional Atp2a2 heterozygous KO mice with ER Ca2+ uptake, neuronal Ca2+ imaging, in vivo microdialysis, and behavior","pmids":["34104969"],"confidence":"Medium","gaps":["Link between Ca2+ kinetics and dopamine release mechanistically indirect","Cell types responsible not isolated"]},{"year":2022,"claim":"Identified Sigmar1 as a direct partner targeting SERCA2 for Hrd1/Sel1L ERAD via K460/K541 ubiquitination, defining a degradative control branch with osteoclast consequences.","evidence":"IP-MS, Co-IP, site-directed mutagenesis, ubiquitination assays, Sigmar1 KO mice, and osteoclast differentiation","pmids":["35611810"],"confidence":"Medium","gaps":["Trigger that initiates Sigmar1-driven degradation unclear","Single-lab validation"]},{"year":2023,"claim":"Tied SERCA2 oxidation/inactivation to endothelial and cardiac ischemia-reperfusion injury, with Ser-663 phosphorylation and XO-mediated oxidation as inhibitory events causing Ca2+ overload.","evidence":"Human ischemic hearts, SERCA2-KO mice, mutagenesis, and cytosolic/mitochondrial Ca2+ and CaMKII assays","pmids":["37291092","35836807"],"confidence":"High","gaps":["Kinase responsible for S663 phosphorylation not identified","Therapeutic translation of preventing modification untested"]},{"year":2023,"claim":"Showed MFN2 directly couples SERCA2 to ER-mitochondria contact, regulating mitochondrial Ca2+ supply and survival in CD8+ T cells.","evidence":"Co-IP, PLA, Mfn2 ablation in CD8+ T cells, SERCA2-KO mice, and mitochondrial Ca2+/metabolism measurements","pmids":["37738362"],"confidence":"High","gaps":["Structural basis of the MFN2-SERCA2 interface unknown","Generalizability beyond T cells untested"]},{"year":2023,"claim":"Linked SERCA2-dependent ER Ca2+ to prohormone processing, autophagy, and feedback transcription, broadening pump function into secretory and degradative cell biology.","evidence":"β-cell-specific SERCA2 KO with proinsulin processing analysis; LC3B LIR-motif Co-IP and Ca2+/CaMKK/CREB feedback in TNBC cells","pmids":["37537395","36561988"],"confidence":"Medium","gaps":["Direct vs indirect contributions of SERCA2 to autophagosome formation unresolved","Feedback loop characterized in single cancer model"]},{"year":2023,"claim":"Demonstrated SERCA2 loss drives neurodegenerative and epidermal pathology that is rescuable, with ERK signaling positioned downstream of SERCA2 loss in keratinocyte adhesion failure.","evidence":"CRISPR SERCA2-KO keratinocytes with omics, organotypic epidermis, and MEK inhibitor rescue; retinal Ca2+ imaging with SERCA2 gene delivery and pharmacological activation","pmids":["37561594","39615485"],"confidence":"High","gaps":["How ER Ca2+ loss activates ERK not mechanistically defined","Durability of gene-delivery rescue not established"]},{"year":null,"claim":"It remains unresolved how the diverse activating and inhibitory PTMs and partner interactions are integrated to set SERCA2 activity in a given cell, and what structural transitions couple specific modifications to defined catalytic steps.","evidence":"No single discovery in the corpus integrates the regulatory inputs into a unified structural-kinetic model","pmids":[],"confidence":"Low","gaps":["No structural model linking PTMs to E1/E2 transitions","Hierarchy and crosstalk among regulators undefined","Tissue-specific dominance of regulatory branches unknown"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140657","term_label":"ATP-dependent activity","supporting_discovery_ids":[1,11]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,3,5,6]},{"term_id":"GO:0016787","term_label":"hydrolase activity","supporting_discovery_ids":[1,11]},{"term_id":"GO:0005215","term_label":"transporter activity","supporting_discovery_ids":[1,3]}],"localization":[{"term_id":"GO:0005783","term_label":"endoplasmic reticulum","supporting_discovery_ids":[4,13,12]}],"pathway":[{"term_id":"R-HSA-382551","term_label":"Transport of small molecules","supporting_discovery_ids":[1,3,5,6]},{"term_id":"R-HSA-397014","term_label":"Muscle contraction","supporting_discovery_ids":[25,17,10]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[7,9,10,11]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[0,13,35]},{"term_id":"R-HSA-8953897","term_label":"Cellular responses to stimuli","supporting_discovery_ids":[13,15,8]}],"complexes":["SERCA2-phospholamban complex","SERCA2/AKAP18δ/PDE3A1 signalosome"],"partners":["PLN","PDE3A","AKAP18Δ","CALU","HAX1","MFN2","SIGMAR1","LC3B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P16615","full_name":"Sarcoplasmic/endoplasmic reticulum calcium ATPase 2","aliases":["Calcium pump 2","Calcium-transporting ATPase sarcoplasmic reticulum type, slow twitch skeletal muscle isoform","Endoplasmic reticulum class 1/2 Ca(2+) ATPase"],"length_aa":1042,"mass_kda":114.8,"function":"This magnesium-dependent enzyme catalyzes the hydrolysis of ATP coupled with the translocation of calcium from the cytosol to the sarcoplasmic reticulum lumen (PubMed:12542527, PubMed:16402920). Involved in autophagy in response to starvation. Upon interaction with VMP1 and activation, controls ER-isolation membrane contacts for autophagosome formation (PubMed:28890335). Also modulates ER contacts with lipid droplets, mitochondria and endosomes (PubMed:28890335). In coordination with FLVCR2 mediates heme-stimulated switching from mitochondrial ATP synthesis to thermogenesis (By similarity) Involved in the regulation of the contraction/relaxation cycle. Acts as a regulator of TNFSF11-mediated Ca(2+) signaling pathways via its interaction with TMEM64 which is critical for the TNFSF11-induced CREB1 activation and mitochondrial ROS generation necessary for proper osteoclast generation. Association between TMEM64 and SERCA2 in the ER leads to cytosolic Ca(2+) spiking for activation of NFATC1 and production of mitochondrial ROS, thereby triggering Ca(2+) signaling cascades that promote osteoclast differentiation and activation","subcellular_location":"Endoplasmic reticulum membrane; Sarcoplasmic reticulum membrane","url":"https://www.uniprot.org/uniprotkb/P16615/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/ATP2A2","classification":"Common Essential","n_dependent_lines":1202,"n_total_lines":1208,"dependency_fraction":0.9950331125827815},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CANX","stoichiometry":0.2},{"gene":"CYB5R3","stoichiometry":0.2},{"gene":"DDOST","stoichiometry":0.2},{"gene":"EMC4","stoichiometry":0.2},{"gene":"EMC8","stoichiometry":0.2},{"gene":"MMGT1","stoichiometry":0.2},{"gene":"NSDHL","stoichiometry":0.2},{"gene":"PGRMC1","stoichiometry":0.2},{"gene":"PGRMC2","stoichiometry":0.2},{"gene":"SEC61B","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/ATP2A2","total_profiled":1310},"omim":[{"mim_id":"621236","title":"RHABDOMYOLYSIS, SUSCEPTIBILITY TO, 2; RHABDO2","url":"https://www.omim.org/entry/621236"},{"mim_id":"620531","title":"SMALL INTEGRAL MEMBRANE PROTEIN 6; SMIM6","url":"https://www.omim.org/entry/620531"},{"mim_id":"620530","title":"ALLREGULIN; ARLN","url":"https://www.omim.org/entry/620530"},{"mim_id":"620429","title":"TRANSMEMBRANE PROTEIN 64; TMEM64","url":"https://www.omim.org/entry/620429"},{"mim_id":"620235","title":"RHABDOMYOLYSIS, SUSCEPTIBILITY TO, 1; RHABDO1","url":"https://www.omim.org/entry/620235"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nucleoplasm","reliability":"Uncertain"},{"location":"Plasma membrane","reliability":"Uncertain"},{"location":"Primary cilium","reliability":"Additional"},{"location":"Perinuclear theca","reliability":"Additional"},{"location":"Mid piece","reliability":"Additional"},{"location":"End piece","reliability":"Additional"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"heart muscle","ntpm":941.9},{"tissue":"skeletal muscle","ntpm":2675.7},{"tissue":"tongue","ntpm":2586.2}],"url":"https://www.proteinatlas.org/search/ATP2A2"},"hgnc":{"alias_symbol":["SERCA2"],"prev_symbol":["ATP2B","DAR"]},"alphafold":{"accession":"P16615","domains":[{"cath_id":"2.70.150.10","chopping":"3-42_117-240","consensus_level":"medium","plddt":89.9402,"start":3,"end":240},{"cath_id":"3.40.50.1000","chopping":"331-356_602-737","consensus_level":"high","plddt":89.1815,"start":331,"end":737},{"cath_id":"3.40.1110.10","chopping":"361-598","consensus_level":"medium","plddt":91.339,"start":361,"end":598},{"cath_id":"1.20.1110.10","chopping":"758-809_828-992_1011-1042","consensus_level":"medium","plddt":85.5494,"start":758,"end":1042},{"cath_id":"1.10.287","chopping":"48-112","consensus_level":"medium","plddt":78.2685,"start":48,"end":112},{"cath_id":"1.10.287","chopping":"256-307","consensus_level":"medium","plddt":73.6575,"start":256,"end":307}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P16615","model_url":"https://alphafold.ebi.ac.uk/files/AF-P16615-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P16615-F1-predicted_aligned_error_v6.png","plddt_mean":85.44},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ATP2A2","jax_strain_url":"https://www.jax.org/strain/search?query=ATP2A2"},"sequence":{"accession":"P16615","fasta_url":"https://rest.uniprot.org/uniprotkb/P16615.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P16615/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P16615"}},"corpus_meta":[{"pmid":"10080178","id":"PMC_10080178","title":"Mutations in ATP2A2, encoding a Ca2+ pump, cause Darier disease.","date":"1999","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10080178","citation_count":578,"is_preprint":false},{"pmid":"16105684","id":"PMC_16105684","title":"Modulating sarco(endo)plasmic reticulum Ca2+ ATPase 2 (SERCA2) activity: cell biological implications.","date":"2005","source":"Cell calcium","url":"https://pubmed.ncbi.nlm.nih.gov/16105684","citation_count":182,"is_preprint":false},{"pmid":"10441323","id":"PMC_10441323","title":"Spectrum of novel ATP2A2 mutations in patients with Darier's disease.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10441323","citation_count":132,"is_preprint":false},{"pmid":"10441325","id":"PMC_10441325","title":"ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes.","date":"1999","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/10441325","citation_count":124,"is_preprint":false},{"pmid":"12975374","id":"PMC_12975374","title":"Dissection of the functional differences between sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) 1 and 2 isoforms and characterization of Darier disease (SERCA2) mutants by steady-state and transient kinetic analyses.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12975374","citation_count":110,"is_preprint":false},{"pmid":"11121153","id":"PMC_11121153","title":"Mosaicism for ATP2A2 mutations causes segmental Darier's disease.","date":"2000","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11121153","citation_count":108,"is_preprint":false},{"pmid":"35836807","id":"PMC_35836807","title":"SGLT2 inhibitor dapagliflozin reduces endothelial dysfunction and microvascular damage during cardiac ischemia/reperfusion injury through normalizing the XO-SERCA2-CaMKII-coffilin pathways.","date":"2022","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/35836807","citation_count":106,"is_preprint":false},{"pmid":"22240811","id":"PMC_22240811","title":"PPAR-γ activation restores pancreatic islet SERCA2 levels and prevents β-cell dysfunction under conditions of hyperglycemic and cytokine stress.","date":"2012","source":"Molecular endocrinology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/22240811","citation_count":103,"is_preprint":false},{"pmid":"18971376","id":"PMC_18971376","title":"The anti-apoptotic protein HAX-1 interacts with SERCA2 and regulates its protein levels to promote cell survival.","date":"2008","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/18971376","citation_count":92,"is_preprint":false},{"pmid":"11389134","id":"PMC_11389134","title":"Squamous cell tumors in mice heterozygous for a null allele of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump.","date":"2001","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/11389134","citation_count":91,"is_preprint":false},{"pmid":"25593322","id":"PMC_25593322","title":"Regulation of sarcoplasmic reticulum Ca2+ ATPase 2 (SERCA2) activity by phosphodiesterase 3A (PDE3A) in human myocardium: phosphorylation-dependent interaction of PDE3A1 with SERCA2.","date":"2015","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/25593322","citation_count":84,"is_preprint":false},{"pmid":"9202840","id":"PMC_9202840","title":"The relative phospholamban and SERCA2 ratio: a critical determinant of myocardial contractility.","date":"1997","source":"Basic research in cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/9202840","citation_count":83,"is_preprint":false},{"pmid":"11168576","id":"PMC_11168576","title":"Darier disease--novel mutations in ATP2A2 and genotype-phenotype correlation.","date":"2001","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/11168576","citation_count":81,"is_preprint":false},{"pmid":"37738362","id":"PMC_37738362","title":"Mitochondria-ER contact mediated by MFN2-SERCA2 interaction supports CD8+ T cell metabolic fitness and function in tumors.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37738362","citation_count":79,"is_preprint":false},{"pmid":"18388909","id":"PMC_18388909","title":"Lentiviral vector-mediated SERCA2 gene transfer protects against heart failure and left ventricular remodeling after myocardial infarction in rats.","date":"2008","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/18388909","citation_count":78,"is_preprint":false},{"pmid":"27489309","id":"PMC_27489309","title":"SERCA2 Deficiency Impairs Pancreatic β-Cell Function in Response to Diet-Induced Obesity.","date":"2016","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/27489309","citation_count":74,"is_preprint":false},{"pmid":"11387203","id":"PMC_11387203","title":"Plasticity and adaptation of Ca2+ signaling and Ca2+-dependent exocytosis in SERCA2(+/-) mice.","date":"2001","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/11387203","citation_count":60,"is_preprint":false},{"pmid":"16204033","id":"PMC_16204033","title":"Haploinsufficiency of Atp2a2, encoding the sarco(endo)plasmic reticulum Ca2+-ATPase isoform 2 Ca2+ pump, predisposes mice to squamous cell tumors via a novel mode of cancer susceptibility.","date":"2005","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/16204033","citation_count":59,"is_preprint":false},{"pmid":"24390139","id":"PMC_24390139","title":"SERCA2 dysfunction in Darier disease causes endoplasmic reticulum stress and impaired cell-to-cell adhesion strength: rescue by Miglustat.","date":"2014","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/24390139","citation_count":57,"is_preprint":false},{"pmid":"29663107","id":"PMC_29663107","title":"The SERCA2: A Gatekeeper of Neuronal Calcium Homeostasis in the Brain.","date":"2018","source":"Cellular and molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/29663107","citation_count":55,"is_preprint":false},{"pmid":"17116488","id":"PMC_17116488","title":"Alterations in the ATP2A2 gene in correlation with colon and lung cancer.","date":"2006","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/17116488","citation_count":54,"is_preprint":false},{"pmid":"19962989","id":"PMC_19962989","title":"Multiple and diverse coexpression, location, and regulation of additional SERCA2 and SERCA3 isoforms in nonfailing and failing human heart.","date":"2009","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/19962989","citation_count":54,"is_preprint":false},{"pmid":"17005265","id":"PMC_17005265","title":"New perspectives on the role of SERCA2's Ca2+ affinity in cardiac function.","date":"2006","source":"Biochimica et biophysica acta","url":"https://pubmed.ncbi.nlm.nih.gov/17005265","citation_count":54,"is_preprint":false},{"pmid":"28035777","id":"PMC_28035777","title":"Mendelian Disorders of Cornification Caused by Defects in Intracellular Calcium Pumps: Mutation Update and Database for Variants in ATP2A2 and ATP2C1 Associated with Darier Disease and Hailey-Hailey Disease.","date":"2017","source":"Human mutation","url":"https://pubmed.ncbi.nlm.nih.gov/28035777","citation_count":53,"is_preprint":false},{"pmid":"19740751","id":"PMC_19740751","title":"Characterization of calumenin-SERCA2 interaction in mouse cardiac sarcoplasmic reticulum.","date":"2009","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/19740751","citation_count":52,"is_preprint":false},{"pmid":"22472004","id":"PMC_22472004","title":"Redox regulation of SERCA2 is required for vascular endothelial growth factor-induced signaling and endothelial cell migration.","date":"2012","source":"Antioxidants & redox signaling","url":"https://pubmed.ncbi.nlm.nih.gov/22472004","citation_count":52,"is_preprint":false},{"pmid":"23913153","id":"PMC_23913153","title":"Drug-to-antibody ratio (DAR) by UV/Vis spectroscopy.","date":"2013","source":"Methods in molecular biology (Clifton, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/23913153","citation_count":50,"is_preprint":false},{"pmid":"35414872","id":"PMC_35414872","title":"A homogeneous high-DAR antibody-drug conjugate platform combining THIOMAB antibodies and XTEN polypeptides.","date":"2022","source":"Chemical science","url":"https://pubmed.ncbi.nlm.nih.gov/35414872","citation_count":49,"is_preprint":false},{"pmid":"20019150","id":"PMC_20019150","title":"Reduced SERCA2 abundance decreases the propensity for Ca2+ wave development in ventricular myocytes.","date":"2009","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/20019150","citation_count":48,"is_preprint":false},{"pmid":"21113058","id":"PMC_21113058","title":"Mitochondrial transcription factors TFAM and TFB2M regulate Serca2 gene transcription.","date":"2010","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/21113058","citation_count":47,"is_preprint":false},{"pmid":"34814703","id":"PMC_34814703","title":"AKAP18δ Anchors and Regulates CaMKII Activity at Phospholamban-SERCA2 and RYR.","date":"2021","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/34814703","citation_count":43,"is_preprint":false},{"pmid":"33334123","id":"PMC_33334123","title":"JNK2, a Newly-Identified SERCA2 Enhancer, Augments an Arrhythmic [Ca2+]SR Leak-Load Relationship.","date":"2020","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/33334123","citation_count":43,"is_preprint":false},{"pmid":"15840101","id":"PMC_15840101","title":"Effects of ultraviolet B irradiation, proinflammatory cytokines and raised extracellular calcium concentration on the expression of ATP2A2 and ATP2C1.","date":"2005","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15840101","citation_count":40,"is_preprint":false},{"pmid":"27997597","id":"PMC_27997597","title":"Immunogenicity and Protective Efficacy of the DAR-901 Booster Vaccine in a Murine Model of Tuberculosis.","date":"2016","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/27997597","citation_count":40,"is_preprint":false},{"pmid":"37291092","id":"PMC_37291092","title":"SERCA2 phosphorylation at serine 663 is a key regulator of Ca2+ homeostasis in heart diseases.","date":"2023","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/37291092","citation_count":38,"is_preprint":false},{"pmid":"15888147","id":"PMC_15888147","title":"Effects of drugs and anticytokine antibodies on expression of ATP2A2 and ATP2C1 in cultured normal human keratinocytes.","date":"2005","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15888147","citation_count":37,"is_preprint":false},{"pmid":"11244492","id":"PMC_11244492","title":"Exclusion of the Darier's disease gene, ATP2A2, as a common susceptibility gene for bipolar disorder.","date":"2001","source":"Molecular psychiatry","url":"https://pubmed.ncbi.nlm.nih.gov/11244492","citation_count":36,"is_preprint":false},{"pmid":"15362510","id":"PMC_15362510","title":"Increased inhibition of SERCA2 by phospholamban in the type I diabetic heart.","date":"2004","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15362510","citation_count":35,"is_preprint":false},{"pmid":"35611810","id":"PMC_35611810","title":"Sigma-1 receptor attenuates osteoclastogenesis by promoting ER-associated degradation of SERCA2.","date":"2022","source":"EMBO molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/35611810","citation_count":34,"is_preprint":false},{"pmid":"25181347","id":"PMC_25181347","title":"Epigenetic switch at atp2a2 and myh7 gene promoters in pressure overload-induced heart failure.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25181347","citation_count":34,"is_preprint":false},{"pmid":"22277942","id":"PMC_22277942","title":"SERCA2-controlled Ca²+-dependent keratinocyte adhesion and differentiation is mediated via the sphingolipid pathway: a therapeutic target for Darier's disease.","date":"2012","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22277942","citation_count":34,"is_preprint":false},{"pmid":"22045735","id":"PMC_22045735","title":"Protein aggregation of SERCA2 mutants associated with Darier disease elicits ER stress and apoptosis in keratinocytes.","date":"2011","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22045735","citation_count":33,"is_preprint":false},{"pmid":"15099360","id":"PMC_15099360","title":"Mutational analysis of the ATP2A2 gene in two Darier disease families with intrafamilial variability.","date":"2004","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15099360","citation_count":31,"is_preprint":false},{"pmid":"24284412","id":"PMC_24284412","title":"Amyloid beta a4 precursor protein-binding family B member 1 (FE65) interactomics revealed synaptic vesicle glycoprotein 2A (SV2A) and sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) as new binding proteins in the human brain.","date":"2013","source":"Molecular & cellular proteomics : MCP","url":"https://pubmed.ncbi.nlm.nih.gov/24284412","citation_count":31,"is_preprint":false},{"pmid":"32375037","id":"PMC_32375037","title":"Islet O-GlcNAcylation Is Required for Lipid Potentiation of Insulin Secretion through SERCA2.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/32375037","citation_count":30,"is_preprint":false},{"pmid":"9461473","id":"PMC_9461473","title":"A novel E box/AT-rich element is required for muscle-specific expression of the sarcoplasmic reticulum Ca2+-ATPase (SERCA2) gene.","date":"1998","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/9461473","citation_count":29,"is_preprint":false},{"pmid":"17287366","id":"PMC_17287366","title":"Phenylephrine hypertrophy, Ca2+-ATPase (SERCA2), and Ca2+ signaling in neonatal rat cardiac myocytes.","date":"2007","source":"American journal of physiology. Cell physiology","url":"https://pubmed.ncbi.nlm.nih.gov/17287366","citation_count":28,"is_preprint":false},{"pmid":"12829175","id":"PMC_12829175","title":"The MKK6-p38 MAPK pathway prolongs the cardiac contractile calcium transient, downregulates SERCA2, and activates NF-AT.","date":"2003","source":"Cardiovascular research","url":"https://pubmed.ncbi.nlm.nih.gov/12829175","citation_count":28,"is_preprint":false},{"pmid":"31778646","id":"PMC_31778646","title":"DEL-1 ameliorates high-fat diet-induced insulin resistance in mouse skeletal muscle through SIRT1/SERCA2-mediated ER stress suppression.","date":"2019","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/31778646","citation_count":27,"is_preprint":false},{"pmid":"32116663","id":"PMC_32116663","title":"Role of TG2-Mediated SERCA2 Serotonylation on Hypoxic Pulmonary Vein Remodeling.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/32116663","citation_count":26,"is_preprint":false},{"pmid":"26154588","id":"PMC_26154588","title":"Somatic ATP2A2 mutation in a case of papular acantholytic dyskeratosis: mosaic Darier disease.","date":"2015","source":"Journal of cutaneous pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26154588","citation_count":26,"is_preprint":false},{"pmid":"11390201","id":"PMC_11390201","title":"Novel mutations of ATP2A2 gene in Japanese patients of Darier's disease.","date":"2001","source":"Journal of dermatological science","url":"https://pubmed.ncbi.nlm.nih.gov/11390201","citation_count":26,"is_preprint":false},{"pmid":"34104969","id":"PMC_34104969","title":"Brain-specific heterozygous loss-of-function of ATP2A2, endoplasmic reticulum Ca2+ pump responsible for Darier's disease, causes behavioral abnormalities and a hyper-dopaminergic state.","date":"2021","source":"Human molecular genetics","url":"https://pubmed.ncbi.nlm.nih.gov/34104969","citation_count":25,"is_preprint":false},{"pmid":"16552539","id":"PMC_16552539","title":"Five mutations of ATP2A2 gene in Chinese patients with Darier's disease and a literature review of 86 cases reported in China.","date":"2006","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/16552539","citation_count":24,"is_preprint":false},{"pmid":"37561594","id":"PMC_37561594","title":"Targeting SERCA2 in organotypic epidermis reveals MEK inhibition as a therapeutic strategy for Darier disease.","date":"2023","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/37561594","citation_count":24,"is_preprint":false},{"pmid":"32446846","id":"PMC_32446846","title":"LncRNA MEG3-210 regulates endometrial stromal cells migration, invasion and apoptosis through p38 MAPK and PKA/SERCA2 signalling via interaction with Galectin-1 in endometriosis.","date":"2020","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/32446846","citation_count":24,"is_preprint":false},{"pmid":"25008120","id":"PMC_25008120","title":"Extracellular signal-regulated kinase activation during cardiac hypertrophy reduces sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) transcription.","date":"2014","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25008120","citation_count":23,"is_preprint":false},{"pmid":"36983052","id":"PMC_36983052","title":"Cadmium Disrupted ER Ca2+ Homeostasis by Inhibiting SERCA2 Expression and Activity to Induce Apoptosis in Renal Proximal Tubular Cells.","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36983052","citation_count":22,"is_preprint":false},{"pmid":"35024244","id":"PMC_35024244","title":"LncEDCH1 improves mitochondrial function to reduce muscle atrophy by interacting with SERCA2.","date":"2021","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/35024244","citation_count":22,"is_preprint":false},{"pmid":"35325010","id":"PMC_35325010","title":"Toxoplasma gondii phosphatidylserine flippase complex ATP2B-CDC50.4 critically participates in microneme exocytosis.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/35325010","citation_count":21,"is_preprint":false},{"pmid":"30575439","id":"PMC_30575439","title":"HIF-1 regulation of miR-29c impairs SERCA2 expression and cardiac contractility.","date":"2018","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/30575439","citation_count":21,"is_preprint":false},{"pmid":"32035136","id":"PMC_32035136","title":"Inactivation of cysteine 674 in the SERCA2 accelerates experimental aortic aneurysm.","date":"2020","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/32035136","citation_count":21,"is_preprint":false},{"pmid":"21057045","id":"PMC_21057045","title":"Silencing calcineurin A subunit reduces SERCA2 expression in cardiac myocytes.","date":"2010","source":"American journal of physiology. Heart and circulatory physiology","url":"https://pubmed.ncbi.nlm.nih.gov/21057045","citation_count":21,"is_preprint":false},{"pmid":"8930809","id":"PMC_8930809","title":"Molecular cloning and analysis of the human cardiac sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2) gene promoter.","date":"1996","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/8930809","citation_count":21,"is_preprint":false},{"pmid":"36876489","id":"PMC_36876489","title":"Disruption of Phosphodiesterase 3A Binding to SERCA2 Increases SERCA2 Activity and Reduces Mortality in Mice With Chronic Heart Failure.","date":"2023","source":"Circulation","url":"https://pubmed.ncbi.nlm.nih.gov/36876489","citation_count":20,"is_preprint":false},{"pmid":"15169625","id":"PMC_15169625","title":"Dispersion of ventricular mRNA of RyR2 and SERCA2 associated with arrhythmogenesis in rats.","date":"2004","source":"Acta pharmacologica Sinica","url":"https://pubmed.ncbi.nlm.nih.gov/15169625","citation_count":20,"is_preprint":false},{"pmid":"15713129","id":"PMC_15713129","title":"High frequency of partial DIIIa and DAR alleles found in sickle cell disease patients suggests increased risk of alloimmunization to RhD.","date":"2005","source":"Transfusion medicine (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/15713129","citation_count":20,"is_preprint":false},{"pmid":"38291059","id":"PMC_38291059","title":"Rescuing SERCA2 pump deficiency improves bone mechano-responsiveness in type 2 diabetes by shaping osteocyte calcium dynamics.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38291059","citation_count":19,"is_preprint":false},{"pmid":"12072062","id":"PMC_12072062","title":"Mutation analysis of the ATP2A2 gene in Taiwanese patients with Darier's disease.","date":"2002","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12072062","citation_count":19,"is_preprint":false},{"pmid":"36561988","id":"PMC_36561988","title":"Highly expressed SERCA2 triggers tumor cell autophagy and is a druggable vulnerability in triple-negative breast cancer.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/36561988","citation_count":19,"is_preprint":false},{"pmid":"16789147","id":"PMC_16789147","title":"New Late Gene, dar, Involved in DNA Replication of Bacteriophage T4 I. Isolation, Characterization, and Genetic Location.","date":"1975","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/16789147","citation_count":19,"is_preprint":false},{"pmid":"23516438","id":"PMC_23516438","title":"Low density lipoproteins promote unstable calcium handling accompanied by reduced SERCA2 and connexin-40 expression in cardiomyocytes.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23516438","citation_count":19,"is_preprint":false},{"pmid":"37195706","id":"PMC_37195706","title":"Association of Somatic ATP2A2 Damaging Variants With Grover Disease.","date":"2023","source":"JAMA dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/37195706","citation_count":18,"is_preprint":false},{"pmid":"33591571","id":"PMC_33591571","title":"Inactivation of SERCA2 Cys674 accelerates aortic aneurysms by suppressing PPARγ.","date":"2021","source":"British journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33591571","citation_count":18,"is_preprint":false},{"pmid":"27106560","id":"PMC_27106560","title":"Loss of function mutations in ATP2A2 and psychoses: A case report and literature survey.","date":"2016","source":"Psychiatry and clinical neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/27106560","citation_count":18,"is_preprint":false},{"pmid":"38273339","id":"PMC_38273339","title":"Incidence of catheter-associated urinary tract infections by Gram-negative bacilli and their ESBL and carbapenemase production in specialized hospitals of Bahir Dar, northwest Ethiopia.","date":"2024","source":"Antimicrobial resistance and infection control","url":"https://pubmed.ncbi.nlm.nih.gov/38273339","citation_count":18,"is_preprint":false},{"pmid":"31120957","id":"PMC_31120957","title":"CD4+ T cell cytokine responses to the DAR-901 booster vaccine in BCG-primed adults: A randomized, placebo-controlled trial.","date":"2019","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/31120957","citation_count":18,"is_preprint":false},{"pmid":"37537395","id":"PMC_37537395","title":"SERCA2 regulates proinsulin processing and processing enzyme maturation in pancreatic beta cells.","date":"2023","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/37537395","citation_count":17,"is_preprint":false},{"pmid":"31826997","id":"PMC_31826997","title":"Different Degrees of 5'-to-3' DAR Interactions Modulate Zika Virus Genome Cyclization and Host-Specific Replication.","date":"2020","source":"Journal of virology","url":"https://pubmed.ncbi.nlm.nih.gov/31826997","citation_count":17,"is_preprint":false},{"pmid":"38909775","id":"PMC_38909775","title":"Novel SERCA2 inhibitor Diphyllin displays anti-tumor effect in non-small cell lung cancer by promoting endoplasmic reticulum stress and mitochondrial dysfunction.","date":"2024","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/38909775","citation_count":16,"is_preprint":false},{"pmid":"22096575","id":"PMC_22096575","title":"SERCA2 regulates non-CF and CF airway epithelial cell response to ozone.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22096575","citation_count":16,"is_preprint":false},{"pmid":"9139974","id":"PMC_9139974","title":"Modulation of SERCA2 expression by thyroid hormone and norepinephrine in cardiocytes: role of contractility.","date":"1997","source":"The American journal of physiology","url":"https://pubmed.ncbi.nlm.nih.gov/9139974","citation_count":16,"is_preprint":false},{"pmid":"22413864","id":"PMC_22413864","title":"Cyclooxygenase-2 inhibition restores ultraviolet B-induced downregulation of ATP2A2/SERCA2 in keratinocytes: possible therapeutic approach of cyclooxygenase-2 inhibition for treatment of Darier disease.","date":"2012","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/22413864","citation_count":16,"is_preprint":false},{"pmid":"32384912","id":"PMC_32384912","title":"SMN-deficiency disrupts SERCA2 expression and intracellular Ca2+ signaling in cardiomyocytes from SMA mice and patient-derived iPSCs.","date":"2020","source":"Skeletal muscle","url":"https://pubmed.ncbi.nlm.nih.gov/32384912","citation_count":16,"is_preprint":false},{"pmid":"36521248","id":"PMC_36521248","title":"Lathyrol promotes ER stress-induced apoptosis and proliferation inhibition in lung cancer cells by targeting SERCA2.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/36521248","citation_count":16,"is_preprint":false},{"pmid":"12366411","id":"PMC_12366411","title":"Expression of sarco/endo-plasmic reticulum Ca2+-ATPase type 2 isoforms (SERCA2) in normal human skin and mucosa, and Darier's disease skin.","date":"2002","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/12366411","citation_count":16,"is_preprint":false},{"pmid":"15186327","id":"PMC_15186327","title":"Identification of mutations in the ATP2A2 gene in patients with Darier's disease from Hungary.","date":"2004","source":"Experimental dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/15186327","citation_count":15,"is_preprint":false},{"pmid":"35646520","id":"PMC_35646520","title":"The substitution of SERCA2 redox cysteine 674 promotes pulmonary vascular remodeling by activating IRE1α/XBP1s pathway.","date":"2022","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/35646520","citation_count":15,"is_preprint":false},{"pmid":"25968337","id":"PMC_25968337","title":"Hypoxia-driven sarcoplasmic/endoplasmic reticulum calcium ATPase 2 (SERCA2) downregulation depends on low-density lipoprotein receptor-related protein 1 (LRP1)-signalling in cardiomyocytes.","date":"2015","source":"Journal of molecular and cellular cardiology","url":"https://pubmed.ncbi.nlm.nih.gov/25968337","citation_count":15,"is_preprint":false},{"pmid":"23354458","id":"PMC_23354458","title":"Malondialdehyde and 4-hydroxynonenal adducts are not formed on cardiac ryanodine receptor (RyR2) and sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA2) in diabetes.","date":"2013","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/23354458","citation_count":15,"is_preprint":false},{"pmid":"31273377","id":"PMC_31273377","title":"Pre-treatment and acquired HIV drug resistance in Dar es Salaam, Tanzania in the era of tenofovir and routine viral load monitoring.","date":"2019","source":"The Journal of antimicrobial chemotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/31273377","citation_count":15,"is_preprint":false},{"pmid":"39341129","id":"PMC_39341129","title":"Melatonin protects RPE cells from necroptosis and NLRP3 activation via promoting SERCA2-related intracellular Ca2+ homeostasis.","date":"2024","source":"Phytomedicine : international journal of phytotherapy and phytopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39341129","citation_count":14,"is_preprint":false},{"pmid":"21964539","id":"PMC_21964539","title":"Regulation and rate limiting mechanisms of Ca2+ ATPase (SERCA2) expression in cardiac myocytes.","date":"2011","source":"Molecular and cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/21964539","citation_count":14,"is_preprint":false},{"pmid":"35222514","id":"PMC_35222514","title":"Healthcare Workers' Knowledge and Resource Availability for Care of Sickle Cell Disease in Dar es Salaam, Tanzania.","date":"2022","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35222514","citation_count":14,"is_preprint":false},{"pmid":"39615485","id":"PMC_39615485","title":"Endoplasmic reticulum stress-related deficits in calcium clearance promote neuronal dysfunction that is prevented by SERCA2 gene augmentation.","date":"2024","source":"Cell reports. Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39615485","citation_count":13,"is_preprint":false},{"pmid":"36717246","id":"PMC_36717246","title":"Cardiac Plin5 interacts with SERCA2 and promotes calcium handling and cardiomyocyte contractility.","date":"2023","source":"Life science alliance","url":"https://pubmed.ncbi.nlm.nih.gov/36717246","citation_count":13,"is_preprint":false},{"pmid":"36157491","id":"PMC_36157491","title":"Intranuclear cardiac troponin I plays a functional role in regulating Atp2a2 expression in cardiomyocytes.","date":"2021","source":"Genes & diseases","url":"https://pubmed.ncbi.nlm.nih.gov/36157491","citation_count":13,"is_preprint":false},{"pmid":"18658259","id":"PMC_18658259","title":"Increased FOG-2 in failing myocardium disrupts thyroid hormone-dependent SERCA2 gene transcription.","date":"2008","source":"Circulation research","url":"https://pubmed.ncbi.nlm.nih.gov/18658259","citation_count":13,"is_preprint":false},{"pmid":"8825033","id":"PMC_8825033","title":"Modulation of SERCA2 activity: regulated splicing and interaction with phospholamban.","date":"1995","source":"Bioscience reports","url":"https://pubmed.ncbi.nlm.nih.gov/8825033","citation_count":12,"is_preprint":false},{"pmid":"22814319","id":"PMC_22814319","title":"Acrokeratosis verruciformis of Hopf showing P602L mutation in ATP2A2 and overlapping histopathological features with Darier disease.","date":"2012","source":"The American Journal of dermatopathology","url":"https://pubmed.ncbi.nlm.nih.gov/22814319","citation_count":12,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":56493,"output_tokens":10100,"usd":0.16049,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":20791,"output_tokens":6660,"usd":0.135228,"stage2_stop_reason":"end_turn"},"total_usd":0.295718,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1999,\n      \"finding\": \"Mutations in ATP2A2 (encoding SERCA2, a sarco/endoplasmic reticulum Ca2+-ATPase) cause Darier disease; frameshift, in-frame, splice-site, and missense mutations in functional domains were identified, establishing that SERCA2 loss-of-function disrupts a Ca2+-signalling pathway regulating keratinocyte cell-to-cell adhesion and differentiation.\",\n      \"method\": \"Mutation screening of ATP2A2 gene in DD families; identification of 13 mutations in functional domains\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — direct mutation identification in functional domains replicated across multiple families, foundational mechanistic link between SERCA2 and keratinocyte adhesion/differentiation\",\n      \"pmids\": [\"10080178\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Steady-state and rapid kinetic analyses of SERCA2a and SERCA2b isoforms revealed: SERCA2b has 10-fold lower Ca2+ dissociation rate from E1Ca2 (true high Ca2+ affinity) and slower dephosphorylation than SERCA2a; both SERCA2 isoforms show 2-fold slower E2→E1Ca2 transition than SERCA1a. Ten Darier disease mutants were functionally characterized: uncoupling of Ca2+ translocation from ATP hydrolysis and/or altered partial reaction rates (E1~P→E2-P block, E2-P→E2 rate reduction, or loss of phosphorylation) account for loss of function in 7/10 mutants.\",\n      \"method\": \"Heterologous expression in HEK-293 cells; steady-state and transient kinetic analyses; radioactive Ca2+ transport and phosphorylation assays\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — rigorous in vitro kinetic characterization with multiple mutants and isoforms, multiple orthogonal biochemical methods\",\n      \"pmids\": [\"12975374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Mice heterozygous for a null Atp2a2 allele (SERCA2 haploinsufficiency) develop squamous cell tumors of forestomach, esophagus, oral mucosa, tongue, and skin, without loss of heterozygosity, establishing that reduced SERCA2 Ca2+ pump levels predispose keratinocytes to neoplasia as a primary initiating event.\",\n      \"method\": \"Atp2a2+/- mouse model; Western blot; histopathology; comparison with age/sex-matched wild-type controls\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — defined loss-of-function mouse model with clear phenotypic readout, confirmed by Western blot and histology\",\n      \"pmids\": [\"11389134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"In SERCA2+/- mice, reduced SERCA2 causes shorter cytosolic Ca2+ transients (due to compensatory upregulation of specific plasma membrane Ca2+ pump isoforms) and ~50% reduction in Ca2+ oscillation frequency, yet agonist-stimulated exocytosis is preserved through adaptive upregulation of Ca2+ sensors synaptotagmins I and III, making exocytosis ~10-fold more sensitive to Ca2+.\",\n      \"method\": \"SERCA2+/- mouse model; Ca2+ imaging; exocytosis assays; Western blot for synaptotagmins and plasma membrane Ca2+ pumps\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods in a clean genetic model with defined molecular readouts\",\n      \"pmids\": [\"11387203\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"HAX-1 (anti-apoptotic protein) binds directly to SERCA2 via residues 575–594 of SERCA2's nucleotide-binding domain interacting with HAX-1 C-terminal domain (aa 203–245). Overexpression of HAX-1 downregulates SERCA2 protein levels, reduces ER Ca2+ stores, and promotes cell survival after hypoxia/reoxygenation or thapsigargin treatment; conversely, SERCA2 overexpression abrogates HAX-1's pro-survival effect.\",\n      \"method\": \"Co-immunoprecipitation; deletion mapping; transfection in HEK-293 cells; immunofluorescence; cell viability assays\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal binding domain mapping, functional rescue/overexpression experiments with multiple readouts in single lab\",\n      \"pmids\": [\"18971376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Calumenin (a luminal EF-hand Ca2+-binding protein) interacts with SERCA2 via its residues 132–222 binding to SERCA2 luminal domain L4 (aa 853–892). The interaction is favored in the E1 conformation of SERCA2 (reduced by thapsigargin, vanadate, or ATP). Calumenin knockdown increases SERCA2 Ca2+ sensitivity and enhances Ca2+ transient amplitude in cardiomyocytes.\",\n      \"method\": \"GST pulldown; co-immunoprecipitation; calumenin knockdown in HL-1 cells; oxalate-supported Ca2+ uptake assay; immunocytochemistry\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — in vitro binding domain mapping, functional Ca2+ measurements with KD, multiple orthogonal methods in single lab\",\n      \"pmids\": [\"19740751\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"VEGF activates SERCA2b via •NO-mediated S-glutathiolation of cysteine-674, which stimulates ER Ca2+ uptake and is required for VEGF-induced endothelial cell Ca2+ influx and migration. A C674S SERCA2b mutant is unresponsive to VEGF/•NO-stimulated migration and Ca2+ uptake, and overexpression of glutaredoxin-1 (which reverses S-glutathiolation) blocks these effects.\",\n      \"method\": \"45Ca2+ uptake assay; SERCA2b C674S mutagenesis; adenoviral overexpression; immunochemical detection of S-glutathione adducts; SERCA2 knockdown; Ca2+ imaging\",\n      \"journal\": \"Antioxidants & redox signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstitution via mutagenesis, multiple orthogonal methods (transport assay, migration assay, S-glutathiolation detection, KD), single lab\",\n      \"pmids\": [\"22472004\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Phosphodiesterase 3A1 (PDE3A1) interacts with SERCA2 in a phosphorylation-dependent manner: PKA phosphorylation of PDE3A1 at Ser-292/Ser-293 (unique N-terminal site) promotes its incorporation into a SERCA2/AKAP18 signalosome in human sarcoplasmic reticulum, where it controls a local cAMP pool regulating phospholamban phosphorylation and SERCA2 activity. Deletion of the PDE3A1/2 N-terminus blocks SERCA2 interaction.\",\n      \"method\": \"Co-immunoprecipitation; gel filtration chromatography; immunohistochemistry; recombinant protein interaction assays; serine-to-alanine mutagenesis; SR Ca2+ uptake assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP with recombinant proteins, mutagenesis mapping, functional cAMP/Ca2+ assays, single lab with multiple orthogonal methods\",\n      \"pmids\": [\"25593322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 phosphorylation at serine 663 is increased in ischemic human and mouse hearts. Preventing S663 phosphorylation significantly increases SERCA2 activity and protects against cytosolic and mitochondrial Ca2+ overload and cell death, establishing S663 phosphorylation as a negative regulator of SERCA2 activity and a pathophysiological event in cardiac ischemia-reperfusion.\",\n      \"method\": \"Phosphorylation analysis in human ischemic hearts; mutagenesis; SERCA2 activity assays; cytosolic/mitochondrial Ca2+ measurements; cell death assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — human tissue validation combined with mechanistic mutagenesis and functional Ca2+ measurements in multiple cell lines\",\n      \"pmids\": [\"37291092\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PDE3A binds directly to SERCA2 via PDE3A amino acids 277–402 interacting with SERCA2 actuator domain (aa 169–216). Disruption of this interaction with a peptide disruptor (OptF) increases SERCA2 activity independently of PLB and PKA, reduces cardiac mortality after aortic banding in mice, and has no effect in cardiomyocyte-specific SERCA2-inactivated mice, confirming the mechanism is SERCA2-dependent.\",\n      \"method\": \"Surface plasmon resonance; proximity ligation assay; peptide arrays; immunoprecipitation; SR Ca2+ uptake in cardiomyocytes and HEK293 vesicles; rAAV9 in vivo gene delivery; echocardiography; cardiac MRI\",\n      \"journal\": \"Circulation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — direct binding characterization, mutagenesis/deletion mapping, functional assays in multiple systems including in vivo rescue, confirmed in SERCA2-KO control\",\n      \"pmids\": [\"36876489\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"AKAP18δ anchors CaMKIIδ to SERCA2-PLN and RYR complexes via two distinct regions: AKAP18δ-N inhibits CaMKIIδ (and binds CaM), while AKAP18δ-C activates CaMKIIδ by lowering the Ca2+ threshold and inducing CaM trapping. AKAP18δ-C facilitates faster Ca2+ reuptake via SERCA2, while AKAP18δ-N has opposite effects, defining AKAP18δ as both a CaM-KAP and a CaMKII regulator at SERCA2-PLN.\",\n      \"method\": \"Peptide arrays; co-immunoprecipitation; pulldown; proximity ligation; FRET-based CaMKII activity assay; SR vesicle Ca2+ imaging; surface plasmon resonance; AlphaScreen; adenovirus/AAV transduction\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods including direct binding, functional kinase and Ca2+ assays, in vivo confirmation\",\n      \"pmids\": [\"34814703\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"JNK2 (but not JNK1) associates with and phosphorylates SERCA2, increasing SERCA2 ATPase maximal rate (without altering Ca2+ affinity) and SR Ca2+ content load. This JNK2-driven SERCA2 activation is CaMKII-independent and, combined with JNK2-CaMKII-driven SR Ca2+ leak, exacerbates atrial arrhythmogenicity.\",\n      \"method\": \"Co-immunoprecipitation; biochemical phosphorylation assay; confocal Ca2+ imaging; SERCA2 ATPase activity assay; optical mapping in intact hearts; JNK-specific inhibition\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding shown by Co-IP, enzymatic activity directly measured, functional Ca2+ and arrhythmia readouts, multiple orthogonal methods\",\n      \"pmids\": [\"33334123\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"MFN2 (mitofusin-2) interacts with ER-embedded SERCA2, enhancing mitochondria-ER contact and facilitating mitochondrial Ca2+ influx required for mitochondrial metabolism. MFN2 also stimulates SERCA2 ER Ca2+ retrieval activity, preventing excessive mitochondrial Ca2+ accumulation and apoptosis in CD8+ T cells. The beneficial effects were largely prevented in SERCA2-knockout mice.\",\n      \"method\": \"Co-immunoprecipitation; proximity ligation assay; genetic ablation of Mfn2 in CD8+ T cells; SERCA2-knockout mice; mitochondrial Ca2+ and metabolism measurements\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal Co-IP, genetic KO validation in two orthologous models, multiple functional readouts\",\n      \"pmids\": [\"37738362\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Darier disease keratinocytes display constitutive ER stress with impaired membrane localization of desmosomal cadherins (Dsg3, Dsc3), desmoplakin, E-cadherin, and catenins (retained in ER), and reduced intercellular adhesion strength. SERCA2 inhibition by thapsigargin in normal keratinocytes recapitulates these abnormalities, establishing SERCA2 loss-of-function as the cause of ER stress and defective desmosome/adherens junction formation in DD.\",\n      \"method\": \"Immunostaining; co-immunostaining with ER markers; dispase mechanical dissociation assay; thapsigargin treatment of normal keratinocytes; Miglustat pharmacological rescue\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function (DD keratinocytes + chemical inhibitor) with multiple molecular and functional readouts, pharmacological rescue\",\n      \"pmids\": [\"24390139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"SERCA2b loss-of-function (via thapsigargin inhibition or siRNA) in keratinocytes increases sphingosine levels and decreases sphingosine kinase (SPHK1) expression. Inhibiting sphingosine lyase rescues defects in keratinocyte differentiation, E-cadherin localization, desmoplakin translocation, and ER Ca2+ sequestration caused by SERCA2 inhibition, linking SERCA2-controlled ER Ca2+ to sphingolipid signaling in keratinocyte adhesion.\",\n      \"method\": \"SERCA2b siRNA knockdown; thapsigargin inhibition; sphingolipid pathway inhibitors; immunofluorescence; Ca2+ sequestration assay\",\n      \"journal\": \"The Journal of investigative dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined molecular pathway readouts, pharmacological pathway rescue, single lab\",\n      \"pmids\": [\"22277942\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"SERCA2 mutant proteins associated with Darier disease are less soluble, aggregate, and are more polyubiquitinated in keratinocytes. Aggregated SERCA2 mutants (not ER Ca2+ depletion per se) initiate ER stress. Mutant SERCA2 aggregates in primary human keratinocytes cause cell rounding, detachment, and apoptosis; conversely, SERCA2 knockdown renders cells resistant to apoptosis.\",\n      \"method\": \"Expression of DD mutants in primary human keratinocytes; solubility/aggregation assays; ubiquitination assay; ER stress markers; cell death/apoptosis assays; SERCA2 knockdown\",\n      \"journal\": \"Journal of cell science\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — systematic analysis of multiple mutants with orthogonal assays in primary cells, single lab\",\n      \"pmids\": [\"22045735\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Haploinsufficiency of Atp2a2 predisposes mice to squamous cell tumors via a novel mechanism not involving loss of heterozygosity (tumor cells retain the wild-type allele and express SERCA2 protein), absence of ras mutations, and upregulation of wild-type K-ras. Affected epithelium shows overexpression of hyperactivation-associated keratins as early as 2 months of age.\",\n      \"method\": \"Laser capture microdissection; immunoblot; immunohistochemistry; ras mutation analysis; Atp2a2+/- mouse model\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic mouse model with molecular characterization of tumor mechanism, multiple analytical methods, single lab\",\n      \"pmids\": [\"16204033\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Reduced SERCA2 abundance (53% reduction) in inducible cardiomyocyte-specific knockout mice decreases SR Ca2+ content, Ca2+ transient amplitude and decay, and reduces the propensity for arrhythmogenic Ca2+ wave development (waves in 31% KO vs 57% WT cardiomyocytes) and ventricular extrasystoles.\",\n      \"method\": \"Inducible cardiomyocyte-specific Serca2 gene disruption; Fluo-5F Ca2+ imaging; whole-cell voltage clamp; in vivo ECG\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean inducible KO model with multiple Ca2+ imaging and electrophysiology readouts, single lab\",\n      \"pmids\": [\"20019150\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"PPAR-γ directly binds a PPAR response element in the proximal SERCA2 gene promoter (−259 bp region) and transactivates SERCA2b expression in pancreatic β-cells. CDK5-induced phosphorylation of PPAR-γ at Ser-273 reduces SERCA2 expression; pioglitazone (PPAR-γ agonist) prevents this by blocking CDK5-mediated PPAR-γ phosphorylation, restoring SERCA2b levels and protecting against ER stress-induced β-cell death.\",\n      \"method\": \"Luciferase reporter assay; EMSA; chromatin immunoprecipitation; CDK5 inhibitor (roscovitine); Ca2+ imaging; insulin secretion assay\",\n      \"journal\": \"Molecular endocrinology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct promoter binding confirmed by ChIP and EMSA, functional rescue with pharmacological tools, single lab\",\n      \"pmids\": [\"22240811\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Mitochondrial transcription factors TFAM and TFB2M bind to the −122 to −114 nt (TFAM) and −122 to −117 nt (TFB2M) regions of the Serca2 gene promoter in the nucleus of cardiac myocytes, directly regulating SERCA2 gene transcription. Mutation of these binding sites reduces Serca2 transcription.\",\n      \"method\": \"Chromatin immunoprecipitation; fluorescence correlation spectroscopy; luciferase reporter with promoter mutations; immunostaining (nuclear localization); overexpression in cardiac myocytes\",\n      \"journal\": \"Cardiovascular research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct ChIP-confirmed binding with functional mutagenesis validation, single lab\",\n      \"pmids\": [\"21113058\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SERCA2 is O-GlcNAcylated in mouse and human β-cells (identified via OGT-dependent modification), and pharmacological SERCA2 activation rescues palmitate-stimulated insulin secretion in OGT-deficient islets, establishing O-GlcNAcylation of SERCA2 as a mechanism coupling nutrient sensing to β-cell ER Ca2+ function and lipid-potentiated insulin secretion.\",\n      \"method\": \"β-cell-specific OGT knockout mice; O-GlcNAc proteomics; pharmacological SERCA2 activation (CDN1163); insulin secretion assay; in vivo hyperinsulinemic clamp\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model combined with pharmacological rescue and identification of PTM on SERCA2, single lab\",\n      \"pmids\": [\"32375037\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"TG2 (transglutaminase 2) mediates serotonylation of SERCA2 (covalent modification by serotonin) under hypoxia, inhibiting SERCA2 activity and increasing intracellular Ca2+ via TRPC6. TG2 gene silencing or knockout prevents hypoxia-induced SERCA2 serotonylation and attenuates pulmonary vascular remodeling and hypertension in vivo.\",\n      \"method\": \"Co-immunoprecipitation; SERCA2 activity assay; TG2 gene silencing/overexpression; TG2 vascular smooth muscle-specific knockout mice; Fluo-4AM Ca2+ measurement\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP identification of modification, functional activity assay, conditional KO in vivo, single lab\",\n      \"pmids\": [\"32116663\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Inactivation of SERCA2 cysteine 674 (C674S knock-in mice) causes intracellular Ca2+ accumulation that activates calcineurin, promoting nuclear translocation of NFAT and NFκB, resulting in smooth muscle cell phenotypic modulation and accelerating angiotensin II-induced aortic aneurysm development. Calcineurin inhibition reverses SMC modulation.\",\n      \"method\": \"SERCA2 C674S knock-in mouse model; calcineurin inhibitors; NFAT/NFκB nuclear translocation assay; angiotensin II aneurysm model; intracellular Ca2+ measurement\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knock-in model with defined molecular pathway, pharmacological pathway inhibition, single lab\",\n      \"pmids\": [\"32035136\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Sigma-1 receptor (Sigmar1) interacts with SERCA2 at residue Q615, and promotes SERCA2 proteasomal degradation through Hrd1/Sel1L-dependent ER-associated degradation (ERAD), with ubiquitination of SERCA2 at K460 and K541 mediating degradation. This Sigmar1-SERCA2 axis attenuates osteoclastogenesis.\",\n      \"method\": \"IP-mass spectrometry; co-immunoprecipitation; site-directed mutagenesis; ubiquitination assay; Sigmar1 agonist/antagonist treatment; Sigmar1 KO mice; osteoclast differentiation assay\",\n      \"journal\": \"EMBO molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — IP-MS followed by co-IP validation, residue-level mutagenesis, and in vivo KO model, single lab\",\n      \"pmids\": [\"35611810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Brain-specific heterozygous loss of Atp2a2 in mice results in decreased ER Ca2+ uptake activity, slower cytosolic Ca2+ decay after neuronal depolarization, and elevated extracellular dopamine levels in the nucleus accumbens (measured by in vivo dialysis), linking SERCA2 haploinsufficiency in neurons to enhanced dopamine signaling and behavioral abnormalities.\",\n      \"method\": \"Brain-specific conditional Atp2a2 heterozygous KO mice; ER Ca2+ uptake assay in brain membranes; neuronal Ca2+ imaging; in vivo microdialysis; behavioral testing\",\n      \"journal\": \"Human molecular genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean conditional KO with direct Ca2+ measurements and in vivo neurochemistry, single lab\",\n      \"pmids\": [\"34104969\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The relative ratio of phospholamban to SERCA2 is a critical determinant of myocardial contractility: cardiac muscles with lower PLB:SERCA2 ratios (atria vs. ventricle, 4.2-fold lower) show 3-fold faster rates of force development and relaxation; phospholamban knockout hearts (no PLB) show enhanced contractility parameters, establishing PLB as a reversible inhibitor of SERCA2 whose relief by phosphorylation regulates diastolic relaxation.\",\n      \"method\": \"Comparison of atrial vs. ventricular contractility; phospholamban knockout mouse hearts; isolated work-performing heart left-ventricular pressure measurements; Western blot for PLB and SERCA2\",\n      \"journal\": \"Basic research in cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic KO model plus quantitative protein ratio analysis with functional cardiac readouts, single lab\",\n      \"pmids\": [\"9202840\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"ERK1/2 activation during cardiac hypertrophy represses SERCA2 transcription via nuclear factor-κB (NFκB); pharmacological ERK inhibitors preserve SERCA2 mRNA during hypertrophy, and ERK activation alone is sufficient to reduce SERCA2 mRNA, establishing an ERK→NFκB→SERCA2 repression pathway.\",\n      \"method\": \"Neonatal rat ventricular myocyte hypertrophy model; pharmacological ERK inhibitors; NFκB inhibitors; RT-PCR; SERCA2 promoter reporter assay\",\n      \"journal\": \"Journal of molecular and cellular cardiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological pathway dissection with reporter assay and mRNA measurement, multiple inhibitors, single lab\",\n      \"pmids\": [\"25008120\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2-deficient β-cells (βS2KO mice) have reduced ER Ca2+ levels and show decreased expression of active proinsulin processing enzymes PC1/3 and PC2, mis-localization of proinsulin and proPC2 to the ERGIC/cis-Golgi, and increased circulating proinsulin, establishing that SERCA2 regulates prohormone trafficking and processing enzyme maturation through ER Ca2+ homeostasis.\",\n      \"method\": \"β-cell-specific SERCA2 KO mice; Ca2+ imaging; RNA-seq; immunofluorescence; proinsulin processing assays; SERCA2-deficient INS-1 cells\",\n      \"journal\": \"Diabetologia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean cell-type-specific KO model with mechanistic trafficking and processing readouts, confirmed in INS-1 cell model\",\n      \"pmids\": [\"37537395\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 interacts with LC3B via an LIR motif, facilitating WIPI2-independent autophagosome formation in triple-negative breast cancer cells. Autophagy-mediated SERCA2 degradation triggers transcriptional upregulation of SERCA2 through a Ca2+/CaMKK/CREB-1 feedback loop.\",\n      \"method\": \"Co-immunoprecipitation; LIR motif analysis; autophagy flux assays; SERCA2 knockdown/overexpression; Ca2+/CaMKK pathway inhibition; CREB reporter assay\",\n      \"journal\": \"Acta pharmaceutica Sinica. B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP binding, pathway pharmacological dissection with functional readouts, single lab\",\n      \"pmids\": [\"36561988\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"FE65 interacts with SERCA2 in human brain tissue, validated by pulldown/mass spectrometry and co-immunoprecipitation. FE65 knockout neurons show upregulation of SERCA2, and FE65 knockdown in HEK293T cells increases sensitivity to thapsigargin, suggesting FE65 modulates intracellular Ca2+ homeostasis via SERCA2.\",\n      \"method\": \"Pulldown/mass spectrometry from human brain tissue; co-immunoprecipitation; FE65/FE65L1 double KO mouse proteomics; FE65 siRNA knockdown; thapsigargin sensitivity assay\",\n      \"journal\": \"Molecular & cellular proteomics\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — Co-IP validated in human brain, functional link to SERCA2 only via sensitivity assay, limited mechanistic follow-up\",\n      \"pmids\": [\"24284412\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"FOG-2 (friend of GATA-2) physically interacts with thyroid hormone receptor-α1 and abrogates T3-mediated SERCA2 promoter activity and expression; cardiac-specific FOG-2 overexpression in mice reduces SERCA2 transcript and protein levels, depresses cardiac function, and activates fetal gene program.\",\n      \"method\": \"Co-immunoprecipitation of FOG-2 with TR-α1; luciferase reporter assay of SERCA2 promoter; FOG-2 transgenic mice; Western blot; RT-PCR\",\n      \"journal\": \"Circulation research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct protein interaction plus in vivo transgenic model with SERCA2 functional readout, single lab\",\n      \"pmids\": [\"18658259\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 loss in retinal neurons occurs in ocular hypertension and optic nerve crush injury in mice and patients with primary open-angle glaucoma. Pharmacological SERCA2 activation or neuron-specific SERCA2 gene delivery rescues single-cell cytosolic Ca2+ clearance dynamics, reduces ER stress, promotes neuronal survival, and restores visual function in injured mice.\",\n      \"method\": \"Two-photon microscopy Ca2+ imaging; rAAV-mediated SERCA2 neuron-specific gene delivery; pharmacological SERCA2 activation; ER stress markers; retinal ganglion cell survival assay; visual behavior testing\",\n      \"journal\": \"Cell reports. Medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Ca2+ dynamics measurement with gene-delivery rescue plus pharmacological activation, multiple orthogonal functional readouts\",\n      \"pmids\": [\"39615485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SERCA2 oxidation (via xanthine oxidase activation) and inactivation is a key intermediary in ischemia/reperfusion-induced endothelial dysfunction: DAPA inhibits XO-mediated SERCA2 oxidation, preventing cytoplasmic Ca2+ overload and CaMKII activation, and the protective effects of DAPA on microvascular integrity are largely abrogated in SERCA2-knockout mice.\",\n      \"method\": \"SERCA2 knockout mice; human coronary artery endothelial cells; hypoxia/reoxygenation model; Western blot for SERCA2 oxidation; CaMKII activity assay; Ca2+ imaging\",\n      \"journal\": \"Theranostics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — SERCA2-KO used as mechanistic control, Ca2+ and kinase activity measurements, single lab\",\n      \"pmids\": [\"35836807\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The SERCA2 gene contains a muscle-specific enhancer in its distal promoter (−1467 to −1105 bp). An E box/AT-rich element at −1115 bp is critical for maximal enhancer activity and binds a muscle-induced nuclear protein complex; CArG and MCAT elements within this region also bind specific nuclear factors and contribute to overall SERCA2 promoter activation in muscle cells.\",\n      \"method\": \"Deletion analysis; heterologous TK promoter assay in Sol8 muscle cells; gel mobility shift assay; mutagenesis of cis-elements\",\n      \"journal\": \"Nucleic acids research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — functional enhancer mapping with mutagenesis and gel shift, single lab\",\n      \"pmids\": [\"9461473\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Cardiac troponin I (cTnI, encoded by TNNI3) translocates to the nucleus in cardiomyocytes and directly binds to the Atp2a2 promoter region (−239 to −889 bp) at a CCAT motif. TNNI3 gain-of-function increases and loss-of-function decreases SERCA2 mRNA and protein levels, and increases Atp2a2 promoter activity in a luciferase reporter assay.\",\n      \"method\": \"ChIP-seq; luciferase reporter assay; TNNI3 siRNA knockdown and overexpression; Western blot; Ca2+ transient measurement\",\n      \"journal\": \"Genes & diseases\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — ChIP-seq binding and reporter assay validated, but single lab with limited mechanistic follow-up on the SERCA2 regulation mechanism\",\n      \"pmids\": [\"36157491\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SERCA2 depletion in CRISPR/Cas9-generated human keratinocytes lacking SERCA2 causes excess MAPK/ERK signaling and deficiency of desmosomal and cytoskeletal proteins, weakening intercellular adhesion. MEK inhibition rescues adhesive protein expression and keratinocyte sheet integrity even in SERCA2-depleted or SERCA2-inhibited cells, positioning ERK signaling downstream of SERCA2 loss in Darier disease pathogenesis.\",\n      \"method\": \"CRISPR/Cas9 SERCA2 knockout in human keratinocytes; organotypic epidermis; RNA-seq; proteomics; immunostaining; MEK inhibitor treatment; dispase sheet integrity assay\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — human genetic KO model with omics and functional rescue, patient biopsy validation, multiple orthogonal methods\",\n      \"pmids\": [\"37561594\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ATP2A2/SERCA2 is a P-type Ca2+-ATPase of the sarco/endoplasmic reticulum that pumps cytosolic Ca2+ into the ER lumen via an E1/E2 transport cycle; its activity is regulated by direct protein interactions (phospholamban inhibition relieved by PKA/CaMKII phosphorylation, PDE3A1 inhibition via actuator-domain binding, AKAP18δ-anchored CaMKIIδ regulation, calumenin inhibition from the ER lumen, HAX-1-mediated protein level control, and MFN2-mediated ER-mitochondria tethering), by post-translational modifications (S-glutathiolation of C674 activating the pump, serotonylation and S663 phosphorylation inhibiting it, K460/K541 ubiquitination targeting it for ERAD), and by transcriptional regulation (PPAR-γ, TFAM/TFB2M, calcineurin/NFAT pathway, ERK/NFκB repression, thyroid hormone receptor/FOG-2 axis); loss-of-function mutations cause Darier disease through ER stress, impaired desmosome/adherens junction assembly downstream of SERCA2 via ERK hyperactivation, while haploinsufficiency predisposes to squamous cell tumors and neuropsychiatric phenotypes via prolonged cytosolic Ca2+ transients and enhanced dopamine signaling.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ATP2A2 encodes SERCA2, a sarco/endoplasmic reticulum P-type Ca2+-ATPase that pumps cytosolic Ca2+ into the ER/SR lumen through an E1/E2 transport cycle, thereby controlling intracellular Ca2+ homeostasis across keratinocytes, cardiomyocytes, neurons, β-cells, and endothelium [#1, #3]. The pump exists as kinetically distinct SERCA2a and SERCA2b isoforms; rapid-kinetic analysis defined the partial reactions of the catalytic cycle and showed that Darier disease mutations uncouple Ca2+ translocation from ATP hydrolysis or block specific phosphoenzyme transitions [#1]. SERCA2 activity is tuned by a network of direct protein partners and post-translational modifications: phospholamban acts as a reversible inhibitor whose phosphorylation relieves suppression to accelerate cardiac relaxation [#25], PDE3A binds the actuator domain to constrain a local cAMP pool [#7, #9], AKAP18δ anchors CaMKIIδ at the SERCA2-PLN complex to bidirectionally control Ca2+ reuptake [#10], JNK2 phosphorylates and activates the pump [#11], luminal calumenin inhibits it in the E1 state [#5], HAX-1 controls its protein level [#4], and MFN2 tethers it to mitochondria to govern mitochondrial Ca2+ supply [#12]. The pump is further regulated by redox and covalent modifications—activating S-glutathiolation of Cys-674 [#6] versus inhibitory serotonylation [#21], Ser-663 phosphorylation [#8], O-GlcNAcylation [#20], and K460/K541 ubiquitination driving Sigmar1/Hrd1-Sel1L-dependent ERAD [#23]—and at the transcriptional level by PPAR-γ, TFAM/TFB2M, ERK/NF-κB repression, and a thyroid hormone receptor/FOG-2 axis [#18, #19, #26, #30]. Loss-of-function mutations in ATP2A2 cause Darier disease, in which mutant SERCA2 aggregation and ER stress, ERK/MAPK hyperactivation, and disrupted sphingolipid signaling impair desmosome/adherens junction assembly and keratinocyte adhesion [#0, #13, #35]. SERCA2 haploinsufficiency separately predisposes to squamous cell tumors without loss of heterozygosity and produces neuropsychiatric phenotypes through prolonged cytosolic Ca2+ transients and enhanced dopamine signaling [#2, #16, #24].\",\n  \"teleology\": [\n    {\n      \"year\": 1999,\n      \"claim\": \"Established the genetic basis linking SERCA2 to an epidermal disease, defining the pump as essential for keratinocyte adhesion and differentiation rather than only muscle Ca2+ handling.\",\n      \"evidence\": \"Mutation screening of ATP2A2 across Darier disease families, identifying 13 mutations in functional domains\",\n      \"pmids\": [\"10080178\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not resolve how individual mutations alter pump catalysis\", \"Did not establish the downstream signaling defect in keratinocytes\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolved how disease mutations impair pump function at the level of the catalytic cycle, distinguishing SERCA2a/2b kinetics and assigning specific partial-reaction defects to mutants.\",\n      \"evidence\": \"Heterologous expression with steady-state and transient kinetic, Ca2+ transport, and phosphorylation assays in HEK-293 cells\",\n      \"pmids\": [\"12975374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"3/10 mutants not mechanistically explained\", \"No high-resolution structural model of mutant transitions\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrated in vivo consequences of reduced pump dosage—tumor predisposition and altered Ca2+ transient kinetics buffered by compensatory adaptations—showing haploinsufficiency is a primary initiating event.\",\n      \"evidence\": \"Atp2a2+/- mouse models with histopathology, Ca2+ imaging, exocytosis assays, and Western blot\",\n      \"pmids\": [\"11389134\", \"11387203\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism connecting reduced pump to neoplasia not defined here\", \"Compensatory pathways may differ across tissues\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified HAX-1 as a direct partner controlling SERCA2 protein level and ER Ca2+ stores, linking pump abundance to apoptosis resistance.\",\n      \"evidence\": \"Reciprocal Co-IP with deletion mapping, transfection, and viability assays in HEK-293 cells\",\n      \"pmids\": [\"18971376\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which HAX-1 lowers SERCA2 levels unresolved\", \"Physiological relevance in non-transfected tissue untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Defined a luminal, conformation-selective inhibitory interaction (calumenin), broadening regulation of SERCA2 beyond the cytosolic face.\",\n      \"evidence\": \"GST pulldown, Co-IP, calumenin knockdown, and oxalate-supported Ca2+ uptake in HL-1 cells\",\n      \"pmids\": [\"19740751\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of E1-state preference not determined\", \"In vivo significance not tested\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Showed redox modification activates the pump, establishing Cys-674 S-glutathiolation as a NO/VEGF-responsive activating switch governing endothelial Ca2+ and migration.\",\n      \"evidence\": \"C674S mutagenesis, 45Ca2+ uptake, S-glutathione adduct detection, glutaredoxin-1 overexpression, and migration assays\",\n      \"pmids\": [\"22472004\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether C674 modification operates similarly in other cell types not addressed\", \"Crosstalk with other PTMs at the same residue unexplored\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Connected SERCA2-controlled ER Ca2+ to sphingolipid signaling as a mediator of keratinocyte adhesion defects, providing a downstream pathway for Darier disease.\",\n      \"evidence\": \"SERCA2b siRNA and thapsigargin in keratinocytes with sphingolipid pathway inhibitors and adhesion/differentiation readouts\",\n      \"pmids\": [\"22277942\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal link between sphingosine and adhesion proteins correlative\", \"Single lab without genetic SERCA2 model\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Reframed Darier disease pathogenesis around mutant protein aggregation and ER stress rather than Ca2+ depletion per se.\",\n      \"evidence\": \"Expression of DD mutants in primary human keratinocytes with solubility, ubiquitination, ER stress, and apoptosis assays plus knockdown\",\n      \"pmids\": [\"22045735\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Aggregation vs depletion contributions not fully separated for all mutants\", \"Single-lab primary cell system\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Demonstrated SERCA2 loss recapitulates the DD adhesion phenotype via ER retention of junctional proteins and constitutive ER stress, with pharmacological rescue.\",\n      \"evidence\": \"DD keratinocytes and thapsigargin in normal keratinocytes with immunostaining, dispase dissociation, and Miglustat rescue\",\n      \"pmids\": [\"24390139\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Signaling intermediary between ER stress and junction assembly not yet identified\", \"Chemical inhibition may not fully mimic genetic loss\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Placed SERCA2 within a phosphorylation-dependent PDE3A1/AKAP18 signalosome that compartmentalizes cAMP to control phospholamban and pump activity.\",\n      \"evidence\": \"Co-IP, gel filtration, recombinant interaction assays, S-to-A mutagenesis, and SR Ca2+ uptake\",\n      \"pmids\": [\"25593322\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry and spatial organization of the signalosome not resolved\", \"Functional consequences in vivo not tested here\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Identified TFAM and TFB2M as direct nuclear transcriptional regulators of Serca2, expanding control beyond muscle-specific enhancers.\",\n      \"evidence\": \"ChIP, fluorescence correlation spectroscopy, and promoter-mutation luciferase reporters in cardiac myocytes\",\n      \"pmids\": [\"21113058\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of nuclear localization of mitochondrial factors unclear\", \"Physiological inducers of this regulation not defined\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined a PPAR-γ/CDK5 transcriptional axis governing SERCA2b in β-cells, linking pump expression to metabolic ER-stress protection.\",\n      \"evidence\": \"Luciferase reporter, EMSA, ChIP, CDK5 inhibition, and insulin secretion/Ca2+ assays\",\n      \"pmids\": [\"22240811\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of Ser-273 phosphorylation to SERCA2 not tested\", \"Single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Established an ERK→NF-κB pathway that transcriptionally represses SERCA2 during cardiac hypertrophy, complementing the ERK-driven adhesion defects later seen in skin.\",\n      \"evidence\": \"Neonatal rat ventricular myocyte hypertrophy model with ERK/NF-κB inhibitors, RT-PCR, and promoter reporter\",\n      \"pmids\": [\"25008120\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct NF-κB binding site on SERCA2 promoter not mapped\", \"Pharmacological dissection only\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Expanded the PTM repertoire controlling SERCA2 across tissues—activating O-GlcNAcylation in β-cells, inhibitory TG2-mediated serotonylation in vascular smooth muscle, and calcineurin/NFAT-coupled C674 signaling in aneurysm—each tying pump regulation to a disease context.\",\n      \"evidence\": \"OGT-KO mice and O-GlcNAc proteomics; TG2 silencing/KO with activity and Ca2+ assays; C674S knock-in with calcineurin inhibitors and aneurysm model\",\n      \"pmids\": [\"32375037\", \"32116663\", \"32035136\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Modification site mapping incomplete for some PTMs\", \"Crosstalk among coexisting modifications unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Defined AKAP18δ as a dual CaM/CaMKIIδ regulator at the SERCA2-PLN complex and JNK2 as a CaMKII-independent activating kinase, refining kinase control of Ca2+ reuptake and arrhythmogenesis.\",\n      \"evidence\": \"Peptide arrays, Co-IP, PLA, SPR, FRET CaMKII assays, and SR Ca2+ imaging; Co-IP and ATPase assays with optical mapping for JNK2\",\n      \"pmids\": [\"34814703\", \"33334123\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"JNK2 phosphorylation site on SERCA2 not identified\", \"Integration of opposing AKAP18δ-N/-C activities in vivo incompletely defined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Demonstrated neuronal SERCA2 haploinsufficiency slows Ca2+ decay and elevates accumbal dopamine, providing a mechanism for the neuropsychiatric phenotype associated with reduced pump dosage.\",\n      \"evidence\": \"Brain-specific conditional Atp2a2 heterozygous KO mice with ER Ca2+ uptake, neuronal Ca2+ imaging, in vivo microdialysis, and behavior\",\n      \"pmids\": [\"34104969\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Link between Ca2+ kinetics and dopamine release mechanistically indirect\", \"Cell types responsible not isolated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Identified Sigmar1 as a direct partner targeting SERCA2 for Hrd1/Sel1L ERAD via K460/K541 ubiquitination, defining a degradative control branch with osteoclast consequences.\",\n      \"evidence\": \"IP-MS, Co-IP, site-directed mutagenesis, ubiquitination assays, Sigmar1 KO mice, and osteoclast differentiation\",\n      \"pmids\": [\"35611810\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Trigger that initiates Sigmar1-driven degradation unclear\", \"Single-lab validation\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Tied SERCA2 oxidation/inactivation to endothelial and cardiac ischemia-reperfusion injury, with Ser-663 phosphorylation and XO-mediated oxidation as inhibitory events causing Ca2+ overload.\",\n      \"evidence\": \"Human ischemic hearts, SERCA2-KO mice, mutagenesis, and cytosolic/mitochondrial Ca2+ and CaMKII assays\",\n      \"pmids\": [\"37291092\", \"35836807\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Kinase responsible for S663 phosphorylation not identified\", \"Therapeutic translation of preventing modification untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed MFN2 directly couples SERCA2 to ER-mitochondria contact, regulating mitochondrial Ca2+ supply and survival in CD8+ T cells.\",\n      \"evidence\": \"Co-IP, PLA, Mfn2 ablation in CD8+ T cells, SERCA2-KO mice, and mitochondrial Ca2+/metabolism measurements\",\n      \"pmids\": [\"37738362\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of the MFN2-SERCA2 interface unknown\", \"Generalizability beyond T cells untested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Linked SERCA2-dependent ER Ca2+ to prohormone processing, autophagy, and feedback transcription, broadening pump function into secretory and degradative cell biology.\",\n      \"evidence\": \"β-cell-specific SERCA2 KO with proinsulin processing analysis; LC3B LIR-motif Co-IP and Ca2+/CaMKK/CREB feedback in TNBC cells\",\n      \"pmids\": [\"37537395\", \"36561988\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect contributions of SERCA2 to autophagosome formation unresolved\", \"Feedback loop characterized in single cancer model\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Demonstrated SERCA2 loss drives neurodegenerative and epidermal pathology that is rescuable, with ERK signaling positioned downstream of SERCA2 loss in keratinocyte adhesion failure.\",\n      \"evidence\": \"CRISPR SERCA2-KO keratinocytes with omics, organotypic epidermis, and MEK inhibitor rescue; retinal Ca2+ imaging with SERCA2 gene delivery and pharmacological activation\",\n      \"pmids\": [\"37561594\", \"39615485\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How ER Ca2+ loss activates ERK not mechanistically defined\", \"Durability of gene-delivery rescue not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how the diverse activating and inhibitory PTMs and partner interactions are integrated to set SERCA2 activity in a given cell, and what structural transitions couple specific modifications to defined catalytic steps.\",\n      \"evidence\": \"No single discovery in the corpus integrates the regulatory inputs into a unified structural-kinetic model\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No structural model linking PTMs to E1/E2 transitions\", \"Hierarchy and crosstalk among regulators undefined\", \"Tissue-specific dominance of regulatory branches unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140657\", \"supporting_discovery_ids\": [1, 11]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 3, 5, 6]},\n      {\"term_id\": \"GO:0016787\", \"supporting_discovery_ids\": [1, 11]},\n      {\"term_id\": \"GO:0005215\", \"supporting_discovery_ids\": [1, 3]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005783\", \"supporting_discovery_ids\": [4, 13, 12]},\n      {\"term_id\": \"GO:0005790\", \"supporting_discovery_ids\": [7]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-382551\", \"supporting_discovery_ids\": [1, 3, 5, 6]},\n      {\"term_id\": \"R-HSA-397014\", \"supporting_discovery_ids\": [25, 17, 10]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 9, 10, 11]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [0, 13, 35]},\n      {\"term_id\": \"R-HSA-8953897\", \"supporting_discovery_ids\": [13, 15, 8]}\n    ],\n    \"complexes\": [\n      \"SERCA2-phospholamban complex\",\n      \"SERCA2/AKAP18δ/PDE3A1 signalosome\"\n    ],\n    \"partners\": [\n      \"PLN\",\n      \"PDE3A\",\n      \"AKAP18δ\",\n      \"CALU\",\n      \"HAX1\",\n      \"MFN2\",\n      \"SIGMAR1\",\n      \"LC3B\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}